



HAL
open science

Straightforward Access to a New Class of Dual DYRK1A/CLK1 Inhibitors Possessing a Simple Dihydroquinoline Core

Mihaela-Liliana Țîntăș, Ludovic Peauger, Florent Alix, Cyril Papamicaël,
Thierry Besson, Jana Sopková-de Oliveira Santos, Vincent Gembus, Vincent
Levacher

► **To cite this version:**

Mihaela-Liliana Țîntăș, Ludovic Peauger, Florent Alix, Cyril Papamicaël, Thierry Besson, et al..
Straightforward Access to a New Class of Dual DYRK1A/CLK1 Inhibitors Possessing a Simple Dihy-
droquinoline Core. *Molecules*, 2023, 28 (1), pp.36. 10.3390/molecules28010036 . hal-03922046

HAL Id: hal-03922046

<https://hal.science/hal-03922046v1>







Submitted on 4 Jan 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Article

Straightforward Access to a New Class of Dual DYRK1A/CLK1 Inhibitors Possessing a Simple Dihydroquinoline Core

Mihaela-Liliana Țîntăș ¹, Ludovic Peauger ², Florent Alix ², Cyril Papamicaël ^{1,*}, Thierry Besson ¹, Jana Sopková-de Oliveira Santos ³, Vincent Gembus ^{2,*} and Vincent Levacher ^{1,*}

¹ INSA Rouen Normandie, Univ. Rouen Normandie, CNRS UMR 6014 COBRA, FR 3038, F-76000 Rouen, France

² VFP Therapies, 15 Rue François Couperin, 76000 Rouen, France

³ UNICAEN, CERMN (Centre d'Études et de Recherche sur le Médicament de Normandie), Normandie Univ., Bd Becquerel, F-14032 Caen, France

* Correspondence: cyril.papamicael@insa-rouen.fr (C.P.); gembusv@hotmail.fr (V.G.);

vincent.levacher@insa-rouen.fr (V.L.); Tel.: +33-023-552-2485 (V.L.)

Abstract: The DYRK (Dual-specificity tyrosine phosphorylation-regulated kinase) family of protein kinases is involved in the pathogenesis of several neurodegenerative diseases. Among them, the DYRK1A protein kinase is thought to be implicated in Alzheimer's disease (AD) and Down syndrome, and as such, has emerged as an appealing therapeutic target. DYRKs are a subset of the CMGC (CDK, MAPKK, GSK3 and CLK) group of kinases. Within this group of kinases, the CDC2-like kinases (CLKs), such as CLK1, are closely related to DYRKs and have also sparked great interest as potential therapeutic targets for AD. Based on inhibitors previously described in the literature (namely TG003 and INDY), we report in this work a new class of dihydroquinolines exhibiting inhibitory activities in the nanomolar range on *h*DYRK1A and *h*CLK1. Moreover, there is overwhelming evidence that oxidative stress plays an important role in AD. Pleasingly, the most potent dual kinase inhibitor **1p** exhibited antioxidant and radical scavenging properties. Finally, drug-likeness and molecular docking studies of this new class of DYRK1A/CLK1 inhibitors are also discussed in this article.

Keywords: Alzheimer's disease; Down syndrome; *h*DYRK1A; *h*CLK1; dihydroquinoline; dual inhibitor; antioxidant; radical scavenger; molecular docking



Citation: Țîntăș, M.-L.; Peauger, L.; Alix, F.; Papamicaël, C.; Besson, T.; Sopková-de Oliveira Santos, J.; Gembus, V.; Levacher, V.

Straightforward Access to a New Class of Dual DYRK1A/CLK1 Inhibitors Possessing a Simple Dihydroquinoline Core. *Molecules* **2023**, *28*, 36. <https://doi.org/10.3390/molecules28010036>

Academic Editors: Letizia Crocetti and Maris Cinelli

Received: 23 November 2022

Revised: 16 December 2022

Accepted: 19 December 2022

Published: 21 December 2022



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Alzheimer's disease (AD) is a neurodegenerative disease, clinically characterized by a progressive deterioration of cognitive functions, leading to an inexorable decline in functional abilities. In addition, AD patients often present neuropsychiatric and behavioral symptoms such as depression, restlessness and hallucinations leading to a deterioration of their quality of life [1]. The pathogenesis of AD is multifactorial, characterized by specific brain anatomical and pathological abnormalities: a significant extent of oxidative stress associated with the presence of extracellular deposits of amyloid- β (A β) peptide and intraneuronal neurofibrillary tangles [2–4].

Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) is a protein kinase that is abnormally expressed in many diseases such as Down syndrome or AD [5–7]. In the literature, it was reported that DYRK1A is able to phosphorylate both APP on Thr668 [8] and presenilin-1 on Thr354 [9]. When the latter is hyper-phosphorylated, the activity of γ -secretase, one of the proteases that cleave APP, is increased. This leads to an abnormally high production of β -amyloid peptides, the main components of amyloid plaques, that are responsible for neurodegeneration [10,11].

DYRK1A was also found to be involved in the hyperphosphorylation of Tau protein (Tubulin-Associated Unit) [12–16], which triggers Tau to dissociate from neuronal microtubules and, shortly afterwards, causes microtubules to disassemble while leading to the formation of neurofibrillary tangles and final neurodegeneration.

Furthermore, the CDK-like kinase (CLK) family, composed of four isoforms: CLK1, CLK2, CLK3 and CLK4, is also an interesting target for treating AD [7,17–20]. As for DYRK1A, they are dual-specificity kinases. In particular, CLK1 is likely involved in AD by phosphorylating the serine residue in serine/arginine-rich (SR) proteins [19]. SR proteins are a family of splicing factors involved in the alternative splicing of Tau.

Although some natural compounds, such as epigallocatechin-3-gallate (EGCG) [21], harmine [22], and leucettamine B [23], have been identified as potent inhibitors of DYRK1A or CLK1, significant research effort has been devoted to developing synthetic DYRK1A and/or CLK1 inhibitors based on relatively sophisticated heterocyclic scaffolds [7,19,24–28]. A large majority of these kinase inhibitors are type I, that is, they bind to the active form of the kinase in the ATP pocket [29].

As part of a research program seeking new and readily accessible classes of DYRK1A and/or CLK1 kinase inhibitors, our attention was drawn to INDY [(Z)-1-(3-Ethyl-5-hydroxy-2(3H)-benzothiazolylidene)-2-propanone] and its derivatives such as TG003 (its synthetic precursor) and ProINDY (its prodrug), reported by Ogawa [30] and Hagiwara [31], respectively (Figure 1). These DYRK1A/CLK1 inhibitors are all derived from 5-methoxy-2-methylbenzothiazole and show significant structural analogy to the 3-acetyl 7-substituted 1,4-dihydroquinoline derivatives. It is worth mentioning that this new class of dual DYRK1A and CLK1 inhibitors based on a biooxidizable 1,4-dihydroquinoline scaffold may also undergo oxidation into quinolinium salts. That could lead to antioxidant properties going hand in hand with the attenuation of oxidative stress in brain tissues. In the present article, we report the synthesis of these biooxidizable 1,4-dihydroquinoline derivatives, a preliminary in vitro biological evaluation toward DYRK1A and CLK1 kinases, and an examination of their redox properties in various biological media.





Figure 1. INDY, TG003 and ProINDY. INDY and TG003: DYRK1A/CLK1 inhibitors and structural analogies with 3-acetyl 7-substituted 1,4-dihydroquinolines.

2. Results and Discussion


2.1. Synthesis of the Studied Dual hDYRK1A and hCLK1 Inhibitors

Apart from commercial quinoline **6a**, 3-acetyl quinoline derivatives **6b–h** were obtained by reacting the corresponding *o*-nitrobenzaldehyde derivatives **3b–h** with 4,4-dimethoxybutan-2-one **4** in the presence of tin chloride as a reducing reagent (Scheme 1). This domino nitro reduction-Friedländer cyclisation, previously reported in the literature for the preparation of quinoline-3-carboxylic acid esters [32], provided access to the required 3-acetyl quinoline derivatives **6b–h** in a one-step procedure from readily available and stable starting materials.



Scheme 1. (i) SnCl₂·H₂O, EtOH, reflux, 4 h (16–96%); (ii) TMSCl, methanol, 50 °C, 4 h (65%); (iii) SOCl₂, ethanol, 78 °C, 18 h (75%) for **6k**, T3P[®], (CH₃)₂N·HCl, DMF, 130 °C, 18 h for **6l**, CDI, CH₃ONHCH₃·HCl, DMF, NEt₃, 18 h (76%) for **6m**; (iv) CH₃I, CH₃CN, sealed tube, 85 °C, 18 h (70–95%) for **2a–m**, PhCH₂Br, CH₃CN, 85 °C, 3 days (91%) for **2n**, PhCH₂CH₂Br, CH₃CN, 85 °C, 4 days (80%) for **2o**, *n*-PrBr, CH₃CN, 85 °C, 2 days (70%) for **2p**; (v) BNAH, CH₂Cl₂, 20 °C, 4 h (10–86%).

We then focused on the preparation of compounds **6i–m** to investigate the influence of the electron withdrawing group (EWG) at C-3 position of the quinoline ring on the inhibitory activity of the DYRK1A and CLK1 kinases. To this end, the 3-cyano-7-methoxy quinoline **6i** previously reported in our group [33] was reacted with chlorotrimethylsilane and anhydrous methanol [34] to provide methyl ester **6j**. Quinoline ester **6k** was obtained by reacting thionyl chloride on the reported quinoline 3-carboxylic acid **5** [35] in ethanol. Finally **6l,m** were prepared from quinoline derivative **5** using T3P[®] and CDI amide coupling reagents, respectively. Subsequently, quinoline derivatives **6a–m** were subjected to a classical quaternization reaction with alkyl halides to afford the desired quinolinium salts **2a–p**, which were then successfully regioselectively reduced with BNAH to the corresponding 1,4-dihydroquinolines **1a–p**. With the target compounds **1a–p** in hand, readily obtained in a few steps, and in most cases, in a good overall yield, we embarked on an initial biological evaluation of these dihydroquinoline scaffolds as potential new DYRK1A and CLK1 inhibitors (Table 1).

Table 1. Inhibitory activities of dihydroquinoline derivatives on kinases (*hDYRK1A*, *hCLK1*).


Entry	Compd	EWG	R ¹	R ²	R ³	IC ₅₀ nM	
						<i>hDYRK1A</i>	<i>hCLK1</i>
1	1a	COCH ₃	H	H	CH ₃	>10,000	>10,000
2	1b	COCH ₃	CF ₃	H	CH ₃	>10,000	>10,000
3	1c	COCH ₃	N(CH ₃) ₂	H	CH ₃	>10,000	>10,000
4	1d	COCH ₃	Br	H	CH ₃	>10,000	>10,000
5	1e	COCH ₃	H	Cl	CH ₃	>10,000	>10,000
6	1f	COCH ₃	OCH ₃	OCH ₃	CH ₃	>10,000	>10,000
7	1g	COCH ₃	R ¹ = R ² = OCH ₂ O		CH ₃	>10,000	>10,000
8	1h	COCH ₃	OCH ₃	H	CH ₃	385 ± 130	377 ± 158
9	1i	CN	OCH ₃	H	CH ₃	>10,000	>10,000
10	1j	CO ₂ CH ₃	OCH ₃	H	CH ₃	>10,000	1464 ± 253
11	1k	CO ₂ C ₂ H ₅	OCH ₃	H	CH ₃	>10,000	3162 ± 525
12	1l	CON(CH ₃) ₂	OCH ₃	H	CH ₃	>10,000	>10,000
13	1m	CON(CH ₃)OCH ₃	OCH ₃	H	CH ₃	>10,000	>10,000
14	1n	COCH ₃	OCH ₃	H	CH ₂ Ph	3023 ± 150	595 ± 63
15	1o	COCH ₃	OCH ₃	H	(CH ₂) ₂ Ph	1111 ± 203	122 ± 12
16	1p	COCH ₃	OCH ₃	H	<i>n</i> -Pr	153 ± 44	47 ± 13

2.2. In Vitro Evaluation on *hDYRK1A* and *hCLK1* Kinases

We initially focused on the influence of the substitution patterns at the benzene ring by comparing the *hDYRK1A* and *hCLK1* inhibitory activities of a set of dihydroquinolines **1a–h** differently substituted at C-6 and C-7 (EWG = COMe and R³ = Me). To our delight, compound **1h** displayed interesting three-digit nanomolar *hDYRK1A* and *hCLK1* inhibitory activities (Entry 8) comparable to those of INDY and TG003, whereas compounds **1a–d** showed no inhibition on either of the two kinases (Entries 1–4). This first series revealed that a methoxy group at C-7 is essential while an additional substituent at C-6 appears to be deleterious, resulting in a complete loss of the inhibitory activity (Entries 6,7). The influence of the EWG at C-3 position, which is crucial to ensure good stability of the 1,4-dihydroquinoline, was then assessed by replacing the acetyl group in **1h** by a variety of EWGs (nitrile, amides, esters). The resulting compounds **1i–m** turned out to be inactive toward both *hDYRK1A* and *hCLK1* kinases (Entries 9–13), with the sole exception of the ester derivatives **1j,k** that exhibited micromolar *hCLK1* inhibitory activities (Entries 10,11). After demonstrating that both an acetyl group at C-3 position and a methoxy group at C-7 position are required, we turned our attention to the role of the alkyl group on the nitrogen dihydroquinoline scaffold. Compared to *N*-methyl dihydroquinoline **1h**, *N*-benzyl and *N*-phenethyl dihydroquinolines **1n,o** exhibited lower *hDYRK1A* inhibitory activities, while displaying comparable three-digit nanomolar *hCLK1* inhibitory activities (Entries 14,15). Gratifyingly, *N*-propyl dihydroquinoline **1p** turned out to be 2.5-fold more potent than *N*-methyl dihydroquinoline **1h** toward *hDYRK1A* and 8-fold more potent than *N*-methyl dihydroquinoline **1h** toward *hCLK1* (Entries 8,16). To complete this SAR analysis, we sought to determine whether or not the enamine function is a crucial element for this new class of dual DYRK1A/CLK1 inhibitors. To tackle this issue, quinolinium salts **2h** and quinoline **6h** were also evaluated for inhibition of *hDYRK1A*/*hCLK1*. None of

these synthetic intermediates showed inhibitory activities on *hDYRK1A/hCLK1* kinases ($IC_{50} > 10$ mM). These observations led us to conclude that, in addition to the acetyl group at C-3 and the methoxy group at C-7, the enamine-like nitrogen atom is also a prerequisite for inhibition of *hDYRK1A/hCLK1*.

2.3. Evaluation of the Antioxidant and Radical Scavenging Activities of **1p**

Oxidative stress is also an important hallmark of AD [36–40] and is closely linked with the formation of both the neurofibrillary tangles and the amyloid plaques.

A further interesting aspect of this novel class of *hDYRK1A/hCLK1* inhibitors is related to the potential of 1,4-dihydroquinolines **1** to prevent oxidative stress by exhibiting in vivo antioxidant and radical scavenging properties during their conversion to the corresponding quaternium salts **2** in the Central Nervous System (CNS) [35,41].

To evaluate the ability of 1,4-dihydroquinolines **1** to act as antioxidants, we studied their behavior by incubating them in different oxidative media [42] (NAD^+ , mouse brain homogenate, H_2O_2 , riboflavin) (Figure 2). First of all, in vitro stability of the most potent inhibitor **1p** was evaluated in PBS and human plasma at 37 °C. After 3.5 h incubation in these non-oxidizing media, only 3% of the oxidation product **2p** was observed in PBS and 4% in human plasma (8% after 24 h for both media). This finding led us to predict a good stability of **1p** at the periphery. Then, in the presence of the oxidizing medium consisting of 0.2% NAD^+ in PBS, the oxidation rate of dihydroquinoline **1p** was relatively low (5% after 3.5 h and 16% after 24 h). However, the formation of the oxidation product **2p** was shown to be much faster when using 2% NAD^+ (24% after 3.5 h and 77% after 24 h). A similar result was observed when **1p** was exposed to 20% fresh mouse brain homogenate (25% after 3.5 h and 72% after 24 h), while hydrogen peroxide 0.1% appeared to be slightly less effective (13% after 3.5 h and 53% after 24 h). Finally, in vitro oxidation with 0.1% riboflavin showed an extremely rapid oxidative conversion of **1p** into the corresponding quaternary salt **2p** (100% in less than 3.5 h).




Figure 2. In vitro stability of **1p** in various non-oxidizing and oxidizing media.

Finally, the aptitude of **1p** to act as a free radical scavenger was assessed using the rapid, inexpensive and widely used DPPH \bullet (2,2-diphenyl-1-picrylhydrazyl) scavenging method [43]. Dark purple DPPH \bullet is a stable free radical that can accept an electron or

hydrogen to become a stable diamagnetic molecule with the loss of violet color. Interestingly, we were able to determine that dihydroquinoline **1p** exhibited a noticeable radical scavenging activity ($EC_{50} = 128 \mu\text{M}$). Moreover, ^1H NMR experiments conducted in DMSO-d_6 showed that dihydroquinoline **1p** reacts with DPPH^\bullet almost instantly to furnish the corresponding inactive quinolinium salt **2p** (see Supplementary Materials). Thus, this novel class of *hDYRK1A/hCLK1* inhibitors are all the more interesting that they may also potentially display an additional antioxidant activity to combat oxidative stress in AD.

2.4. Drug-likeness Evaluation

Drug candidates should possess favorable ADME (Absorption, Distribution, Metabolism, and Excretion) properties. In the literature, Lipinski [44], based on a study of orally active drugs, established a set of simple rules for estimating permeability. These rules were later adjusted and others were added to design successful CNS drugs [45]. To predict the CNS druggability of **1p**, its ability to cross the blood-brain barrier (BBB) by passive diffusion was examined using the free online server SwissADME [46] (Table 2). According to the results obtained (see Supplementary Materials) and as illustrated by the “BOILED-egg” (Brain Or Intestinal EstimatedD permeation) [47], 1,4-dihydroquinoline **1p** may be viewed as a promising CNS drug candidate. The “BOILED-egg” method is based on a descriptive delineation of well-absorbed drugs. This robust and accurate predictive model of passive absorption is based on the calculation of physicochemical descriptors.

Table 2. Calculation with **1p** and comparison of parameters required for drugs targeting the CNS.

Properties	SwissADME	Required	BOILED-Egg from SwissADME
Molecular weight	245Da	<450Da	
cLogP	2.63	<5	
Hydrogen bond donor	0	<3	
Hydrogen bond acceptor	2	<7	
Number of rotatable bonds	4	<8	
Topological polar surface area	29.5 \AA^2	<60–70 \AA^2	
Aqueous solubility ^a	2.5×10^{-2} to $2.4 \times 10^{-1} \text{ mg}\cdot\text{mL}^{-1}$	$>60 \mu\text{g mL}^{-1}$	

^a Experimental solubility of **1p** in PBS was determined (see Supplementary Materials): 0.6 mM ($0.147 \text{ mg}\cdot\text{mL}^{-1}$).

To confirm these encouraging results, the ability of **1p** to cross the BBB by passive diffusion was assessed through the parallel artificial membrane permeability assay of blood-brain barrier (PAMPA-BBB) [48]. The obtained permeability value suggests that **1p** easily diffuses across the BBB ($P_e = 20.0 \pm 0.9 \times 10^{-6} \text{ cm}\cdot\text{s}^{-1}$).

2.5. Docking Studies

Visualization of the *hDYRK1A* structure co-crystallized with INDY (PDB ID: 3ANQ [30]), a DYRK1A benzothiazole derivative ATP-competitive inhibitor ($IC_{50} = 0.24 \mu\text{M}$ and $K_i = 0.18 \mu\text{M}$), and *hCLK1* co-crystallized with the INDY derivative inhibitor TG003 (PDB ID: 6YTE [49], $K_d = 75 \text{ nM}$) showed that the two ligands bind in both kinases' active sites through a very similar interaction network (Figure 3A,B). In both structures, the aromatic ring of the ligands was placed parallel to the beta sheet delimiting the ATP binding site and the ligands established two hydrogen bonds: (i) a first one with a backbone NH of Leu241-*hDYRK1A* or Leu244-*hCLK1*, and (ii) a second one with NH_3^+ of the Lys188-*hDYRK1A* or Lys191-*hCLK1* side chain. Even though the lysine side chain is long and flexible, in both kinases its orientation is fixed through salt bridges with Glu203-*hDYRK1A* and Glu206-*hCLK1*. Therefore, for a ligand binding in the “INDY way” to the two kinases, it is necessary to have two hydrogen bond acceptors at a distance of about 8.5 \AA . Among the synthesized ligands, only ligands with the $\text{EWG} = \text{COCH}_3$ and R^1 substituent = OCH_3 presented interesting activities. Indeed, the distance between their oxygen atoms is about

8.7 Å. To gain further insight into the binding mode of the dihydroquinoline derivatives, compound **1h** docking studies using the GOLD program applying the ChemPLP scoring function were carried out. GOLD is an automated ligand docking program that uses a genetic algorithm. GOLD's evolutionary algorithm modifies the position, orientation and conformation of a ligand to fit into one or more low energy states of the protein's active site. Our docking studies confirmed that compound **1h** reproduces well the INDY binding mode in *hDYRK1A* and in *hCLK1*. For both kinases, the proposed poses by GOLD converged to the same ligand orientation and the best scoring ones are represented on Figure 3C,D. The compound **1h** ChemPLP fit score was 63.59 in *hDYRK1A* and 67.99 in *hCLK1*. As can be seen on Figure 3, compound **1h** is able to establish the two crucial hydrogen bonds with both kinases, the first one with the Leu backbone NH and the second one with NH_3^+ of Lys.




Figure 3. Two perpendicular views of (A) INDY inhibitor position from the *hDYRK1* X-ray structure, and (B) INDY derivative TG003 position from the *hCLK1* X-ray structure compared to the compound **1h** positioned using the docking studies in the (C) *hDYRK1A* binding site and (D) *hCLK1* binding site. The INDY, INDY derivative TG003, compound **1h** and the selected residue or residue side chains of the binding site are in stick form and the protein in ribbon representation. This figure was made with PYMOL (DeLano Scientific, 2002, San Carlo, CA, USA).

3. Materials and Methods

3.1. Docking Studies

The initial model of compound **1h** was built using BIOVIA Discovery Studio v19.1 (BIOVIA, San Diego, CA, USA) and its preferential protonation state at pH 7.4 was checked using standard tools of the ChemAxon Package (ChemAxon Ltd., Budapest, Hungary) [50]; the majority nonprotonated microspecies was used for the docking studies.

The crystallographic coordinates of *human* CLK1 used in this study were obtained from the X-ray structure of CLK1 bound with the benzothiazole TG003 inhibitor (PDB ID 6YTE [49], a structure refined to 2.30 Å with an R factor of 18.0%) and those of *human* DYRK1A from the X-ray structure of DYRK1A co-crystallized with the INDY inhibitor (PDB ID 3ANQ [30], a structure refined to 2.60 Å with an R factor of 23.6%).

The docking of compound **1h** into the *hCLK1* and *hDYRK1* was carried out with the GOLD program v5.3 (The Cambridge Crystallographic Data Centre CCDC, Cambridge,

United Kingdom) using the default parameters [51,52]. This program applies a genetic algorithm to explore conformational spaces and ligand binding modes. To evaluate the proposed ligand positions, the ChemPLP fitness function was applied. The binding site in both kinases was defined as a 6 Å sphere from the co-crystallized ligand.

3.2. Chemistry

All commercial reagents were used without further purification. The solvents were dried with appropriate desiccants and distilled prior to use or were obtained anhydrous from commercial suppliers. Silica gel (60, 230–400 mesh or 70–230 mesh) was used for column chromatography. Reactions were monitored by thin layer chromatography on silica gel precoated aluminum plates. UV light at 254 nm or KMnO₄ stains were used to visualize TLC plates. ¹H, ¹³C, ¹⁹F NMR spectra were recorded using a spectrometer operating at 300, 75 and 282 MHz, respectively. Abbreviations used for peak multiplicities are s: singlet, d: doublet, t: triplet, q: quadruplet dd = doublet of doublet, br = broad and m: multiplet. Coupling constants *J* are in Hz and chemical shifts are given in ppm and calibrated with DMSO-*d*₆ or CDCl₃ (residual solvent signals). ¹H NMR spectra obtained in CDCl₃ were referenced to 7.26 ppm. ¹³C NMR spectra obtained in CDCl₃ were referenced to 77.16 ppm and in DMSO-*d*₆ were referenced to 39.52 ppm. ¹⁹F NMR chemical shifts (δ) were determined relative to CFCl₃ as an internal standard (¹⁹F, δ = 0.0 ppm). Nitrobenzaldehyde derivatives **3b–e**, **g**, **h** and 4,4-dimethoxybutan-2-one **4** were obtained from Sigma-Aldrich, while **3f** was commercially available at Fisher Scientific. 7-methoxy quinoline carboxylic acid **5** was prepared as previously reported in the literature [33,35,41]. 3-acetylquinoline **6a** was purchased from Fisher Scientific. 7-methoxyquinoline-3-carbonitrile **6i** was prepared using a synthesis previously described [33]. Elemental analyses were performed by the microanalysis service of the University of Rouen and were recorded with a Thermo Scientific™ FLASH 2000 analyzer (Thermo Fisher Scientific, Waltham, MA, USA).

General procedure A for the synthesis of compounds **1a–p**

The corresponding quinolinium salt **2a–p** and BNAH were placed in dry and degassed dichloromethane in a round-bottomed flask and under inert atmosphere. The resulting suspension was stirred in the dark at 20 °C for 4 h. Thereafter, degassed dichloromethane (20 mL) was added to the reaction mixture and the solution was washed with degassed water (2 × 20 mL) and brine. The organic phase was dried on MgSO₄ and evaporated to dryness to give the corresponding dihydroquinoline.

1-(1-Methyl-1,4-dihydroquinolin-3-yl)ethanone (**1a**)

According to procedure A, from quinolinium salt **2a** (150 mg, 0.48 mmol), BNAH (103 mg, 0.48 mmol), dry dichloromethane (2.0 mL). Compound **1a** was obtained (63 mg, 70%) as a brown amorphous solid. ¹H NMR (300 MHz, CDCl₃) δ 7.19–7.07 (m, 3H), 6.99 (dd, *J* = 7.4, 1.2 Hz, 1H), 6.78 (dd, *J* = 8.0, 1.1 Hz, 1H), 3.77 (s, 2H), 3.29 (s, 3H), 2.24 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 194.26, 144.92, 138.45, 129.84, 127.13, 123.82, 123.59, 112.77, 109.45, 39.34, 25.65, 24.12; HRMS (ESI): *m/z* calcd. for C₁₂H₁₄NO: 188.1075 [M + H]⁺, found 188.4068. Anal. Calcd. for C₁₂H₁₃NO: C, 76.98; H, 7.00; N, 7.48. Found: C, 77.09; H, 7.03; N, 7.53.

1-(1-Methyl-7-(trifluoromethyl)-1,4-dihydroquinolin-3-yl)ethanone (**1b**)

According to procedure A, from quinolinium salt **2b** (150 mg, 0.39 mmol), BNAH (84 mg, 0.39 mmol), dry dichloromethane (2.0 mL). Compound **1b** was obtained (66 mg, 66%) as an orange solid. m.p. 141–142 °C; ¹H NMR (300 MHz, CDCl₃) δ 7.22–7.12 (m, 3H), 6.93 (d, *J* = 1.6 Hz, 1H), 3.82–3.70 (m, 2H), 3.30 (s, 3H), 2.24 (s, 3H); ¹⁹F NMR (282 MHz, CDCl₃) δ –62.7; ¹³C NMR (75 MHz, CDCl₃) δ 194.30, 144.47, 139.22, 130.22, 129.67 (q, *J* = 32.5 Hz), 127.80 (d, *J* = 1.4 Hz), 124.08 (q, *J* = 1080 Hz) 120.07 (q, *J* = 3.9 Hz), 109.88, 109.31 (q, *J* = 3.9 Hz), 39.38, 25.69, 24.23; HRMS (ESI): *m/z* calcd. for C₁₃H₁₃F₃NO: 256.0949 [M + H]⁺, found 256.0955. Anal. Calcd. for C₁₃H₁₂F₃NO: C, 61.17; H, 4.74; N, 5.49. Found: C, 61.09; H, 4.83; N, 5.53.

1-(7-(Dimethylamino)-1-methyl-1,4-dihydroquinolin-3-yl)ethanone (**1c**)

According to procedure A, from quinolinium salt **2c** (150 mg, 0.42 mmol), BNAH (90 mg, 0.42 mmol), dry dichloromethane (2.0 mL). Compound **1c** was obtained (65 mg, 67%) as an orange solid. m.p. 126–127 °C; ¹H NMR (300 MHz, CDCl₃) δ 7.14 (d, *J* = 0.8 Hz, 1H), 6.94 (d, *J* = 8.4 Hz, 1H), 6.38 (dd, *J* = 8.3, 2.5 Hz, 1H), 6.12 (d, *J* = 2.4 Hz, 1H), 3.65 (s, 2H), 3.28 (s, 3H), 2.91 (s, 6H), 2.21 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 194.45, 150.19, 145.12, 138.88, 130.23, 111.92, 110.02, 108.19, 97.92, 40.88, 39.41, 24.77, 24.16; HRMS (ESI): *m/z* calcd. for C₁₄H₁₉N₂O: 231.1497 [M + H]⁺, found 231.1494. Anal. Calcd. for C₁₄H₁₈N₂O: C, 73.01; H, 7.88; N, 12.16. Found: C, 72.89; H, 7.82; N, 12.23.

1-(7-Bromo-1-methyl-1,4-dihydroquinolin-3-yl)ethanone (1d)

According to procedure A, from quinolinium salt **2d** (150 mg, 0.38 mmol), BNAH (82 mg, 0.38 mmol), dry dichloromethane (2.0 mL). Compound **1d** was obtained (75 mg, 74%) as a beige solid. m.p. 179–180 °C; ¹H NMR (300 MHz, CDCl₃) δ 7.13–7.05 (m, 2H), 6.95 (dt, *J* = 8.1, 1.1 Hz, 1H), 6.89 (d, *J* = 1.9 Hz, 1H), 3.69 (s, 2H), 3.26 (s, 3H), 2.24 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 194.33, 144.39, 139.93, 131.10, 126.16, 122.72, 120.46, 115.77, 110.09, 39.40, 25.27, 24.25; HRMS (ESI): *m/z* calcd. for C₁₂H₁₃NO⁷⁹Br: 266.0181 [M + H]⁺, found 266.0182. Anal. Calcd. for C₁₂H₁₂NOBr: C, 54.16; H, 4.54; N, 5.26. Found: C, 54.06; H, 4.67; N, 5.23.

1-(6-Chloro-1-methyl-1,4-dihydroquinolin-3-yl)ethanone (1e)

According to procedure A, from quinolinium salt **2e** (150 mg, 0.43 mmol), BNAH (93 mg, 0.43 mmol), dry dichloromethane (2.0 mL). Compound **1e** was obtained (74 mg, 77%) as a beige solid. m.p. 124–125 °C; ¹H NMR (300 MHz, CDCl₃) δ 7.14–7.05 (m, 3H), 6.72–6.65 (m, 1H), 3.73 (d, *J* = 1.1 Hz, 2H), 3.27 (s, 3H), 2.23 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 194.10, 144.52, 137.17, 129.45, 128.34, 126.92, 125.63, 113.91, 109.22, 39.41, 25.60, 24.13; HRMS (ESI): *m/z* calcd. for C₁₂H₁₃NO³⁵Cl: 222.0686 [M + H]⁺, found 222.0692. Anal. Calcd. for C₁₂H₁₂NOCl: C, 65.02; H, 5.46; N, 6.32. Found: C, 64.97; H, 5.53; N, 6.22.

1-(6,7-Dimethoxy-1-methyl-1,4-dihydroquinolin-3-yl)ethanone (1f)

According to procedure A, from quinolinium salt **2f** (160 mg, 0.43 mmol), BNAH (92 mg, 0.43 mmol), dry dichloromethane (2.0 mL). Compound **1f** was obtained (10 mg, 10%) as a yellow solid. m.p. 235–236 °C; ¹H NMR (300 MHz, CDCl₃) δ 7.14 (s, 1H), 6.62 (t, *J* = 0.9 Hz, 1H), 6.38 (s, 1H), 3.87 (s, 3H), 3.83 (s, 3H), 3.70 (s, 2H), 3.30 (s, 3H), 2.22 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 194.29, 147.87, 145.58, 144.72, 131.86, 115.79, 113.28, 108.77, 98.74, 56.49, 56.36, 39.63, 25.62, 24.21; HRMS (ESI): *m/z* calcd. for C₁₄H₁₈NO₃: 248.1287 [M + H]⁺, found 248.1282. Anal. Calcd. for C₁₄H₁₇NO₃: C, 68.00; H, 6.93; N, 5.66. Found: C, 67.91; H, 6.83; N, 5.73.

1-(5-Methyl-5,8-dihydro-[1,3]dioxolo[4,5-g]quinolin-7-yl)ethanone (1g)

According to procedure A, from quinolinium salt **2g** (150 mg, 0.42 mmol), BNAH (90 mg, 0.42 mmol), dry dichloromethane (2.0 mL). Compound **1g** was obtained (65 mg, 67%) as an orange solid. m.p. 152–153 °C; ¹H NMR (300 MHz, CDCl₃) δ 7.09 (s, 1H), 6.55 (t, *J* = 0.9 Hz, 1H), 6.36 (s, 1H), 5.87 (s, 2H), 3.64 (s, 2H), 3.22 (s, 3H), 2.19 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 194.16, 146.71, 144.66, 143.60, 132.73, 116.50, 109.61, 108.49, 101.23, 95.40, 39.88, 25.97, 24.12; HRMS (ESI): *m/z* calcd. for C₁₃H₁₄NO₃: 232.0974 [M + H]⁺, found 232.0975. Anal. Calcd. for C₁₃H₁₃NO₃: C, 67.52; H, 5.67; N, 6.06. Found: C, 67.72; H, 5.63; N, 6.11.

1-(7-Methoxy-1-methyl-1,4-dihydroquinolin-3-yl)ethanone (1h)

According to procedure A, from quinolinium salt **2h** (138 mg, 0.47 mmol), BNAH (100 mg, 0.47 mmol), dry dichloromethane (2.0 mL). Compound **1h** was obtained (83 mg, 82%) as an orange solid. m.p. 99–100 °C; ¹H NMR (300 MHz, CDCl₃) δ 7.14 (d, *J* = 0.8 Hz, 1H), 7.02 (dt, *J* = 8.3, 1.1 Hz, 1H), 6.53 (dd, *J* = 8.3, 2.5 Hz, 1H), 6.35 (d, *J* = 2.4 Hz, 1H), 3.79 (s, 3H), 3.69 (s, 2H), 3.27 (s, 3H), 2.24 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 194.54, 158.97, 144.79, 139.42, 130.46, 116.12, 110.25, 107.36, 100.48, 55.54, 39.52, 24.93, 24.29; HRMS (ESI): *m/z* calcd. for C₁₃H₁₆NO₂: 218.1181 [M + H]⁺, found 218.1191. Anal. Calcd. for C₁₃H₁₅NO₂: C, 71.87; H, 6.96; N, 6.45. Found: C, 71.91; H, 6.93; N, 6.53.

7-Methoxy-1-methyl-1,4-dihydroquinoline-3-carbonitrile (1i)

According to procedure A, from quinolinium salt **2i** (100 mg, 0.31 mmol), BNAH (66 mg, 0.31 mmol), dry dichloromethane (2.0 mL). Compound **1i** was obtained (45 mg, 73%) as a yellow solid. m.p. 127–128 °C; ¹H NMR (300 MHz, CDCl₃) δ 6.88 (dt, *J* = 8.3, 1.0 Hz, 1H), 6.66 (t, *J* = 1.0 Hz, 1H), 6.51 (dd, *J* = 8.3, 2.5 Hz, 1H), 6.29 (d, *J* = 2.4 Hz, 1H), 3.78 (s, 3H), 3.64 (d, *J* = 1.1 Hz, 2H), 3.15 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 159.33, 144.92, 139.15, 129.87, 121.41, 112.54, 107.50, 100.36, 77.51, 55.47, 38.95, 26.68; HRMS (ESI): *m/z* calcd. for C₁₂H₁₃N₂O: 201.1028 [M + H]⁺, found 201.1035. Anal. Calcd. for C₁₂H₁₂N₂O: C, 71.98; H, 6.04; N, 13.99. Found: C, 72.05; H, 5.98; N, 14.08.

Methyl 7-methoxy-1-methyl-1,4-dihydroquinoline-3-carboxylate (1j)

According to procedure A, from quinolinium salt **2j** (100 mg, 0.28 mmol), BNAH (60 mg, 0.28 mmol), dry dichloromethane (2.0 mL). Compound **1j** was obtained (51 mg, 79%) as a yellow solid. m.p. 95–96 °C; ¹H NMR (300 MHz, CDCl₃) δ 7.22 (d, *J* = 0.9 Hz, 1H), 6.97 (dt, *J* = 8.3, 1.1 Hz, 1H), 6.50 (dd, *J* = 8.3, 2.5 Hz, 1H), 6.31 (d, *J* = 2.4 Hz, 1H), 3.79 (s, 3H), 3.72 (d, *J* = 6.7 Hz, 5H), 3.20 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 168.37, 159.00, 143.10, 139.91, 130.24, 115.39, 106.95, 100.20, 97.69, 55.46, 51.13, 39.05, 25.56; HRMS (ESI): *m/z* calcd. for C₁₃H₁₆NO₃: 234.1130 [M + H]⁺, found 234.1135. Anal. Calcd. for C₁₃H₁₅NO₃: C, 66.94; H, 6.48; N, 6.00. Found: C, 67.03; H, 6.53; N, 6.09.

Ethyl 7-methoxy-1-methyl-1,4-dihydroquinoline-3-carboxylate (1k)

According to procedure A, from quinolinium salt **2k** (100 mg, 0.27 mmol), BNAH (58 mg, 0.27 mmol), dry dichloromethane (2.0 mL). Compound **1k** was obtained (57 mg, 86%) as a yellow solid. m.p. 93–94 °C; ¹H NMR (300 MHz, CDCl₃) δ 7.20 (d, *J* = 0.9 Hz, 1H), 6.96 (dt, *J* = 8.3, 1.1 Hz, 1H), 6.49 (dd, *J* = 8.3, 2.5 Hz, 1H), 6.29 (d, *J* = 2.5 Hz, 1H), 4.18 (q, *J* = 7.1 Hz, 2H), 3.78 (s, 3H), 3.69 (d, *J* = 1.1 Hz, 2H), 3.19 (s, 3H), 1.29 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 167.96, 158.99, 142.88, 139.99, 130.22, 115.45, 106.87, 100.14, 98.03, 59.66, 55.46, 39.03, 25.56, 14.69; HRMS (ESI): *m/z* calcd. for C₁₄H₁₈NO₃: 248.1287 [M + H]⁺, found 248.1279. Anal. Calcd. for C₁₄H₁₇NO₃: C, 68.00; H, 6.93; N, 5.66. Found: C, 68.05; H, 6.99; N, 5.59.

7-Methoxy-N,N,1-trimethyl-1,4-dihydroquinoline-3-carboxamide (1l)

According to procedure A, from quinolinium salt **2l** (150 mg, 0.40 mmol), BNAH (86 mg, 0.40 mmol), dry dichloromethane (2.0 mL). Compound **1l** was obtained (59.7 mg, 60%) as a yellow solid. m.p. 219–220 °C; ¹H NMR (300 MHz, CDCl₃) δ 6.92 (dt, *J* = 8.3, 1.0 Hz, 1H), 6.48–6.39 (m, 2H), 6.25 (d, *J* = 2.5 Hz, 1H), 3.76 (s, 3H), 3.65 (d, *J* = 1.1 Hz, 2H), 3.11 (s, 3H), 3.01 (s, 6H); ¹³C NMR (75 MHz, CDCl₃) δ 171.95, 159.04, 141.19, 138.15, 129.58, 114.53, 105.96, 102.37, 99.17, 55.39, 38.49, 37.79, 27.75; HRMS (ESI): *m/z* calcd. for C₁₄H₁₉N₂O₂: 247.1447 [M + H]⁺, found 247.1457. Anal. Calcd. For C₁₄H₁₈N₂O₂: C, 68.27; H, 7.37; N, 11.37. Found: C, 68.07; H, 7.18; N, 11.29.

N,7-Dimethoxy-N,1-dimethyl-1,4-dihydroquinoline-3-carboxamide (1m)

According to procedure A, from quinolinium salt **2m** (150 mg, 0.39 mmol), BNAH (83 mg, 0.39 mmol), dry dichloromethane (3.0 mL). Compound **1m** was obtained (68 mg, 67%) as a yellow solid. ¹H NMR (300 MHz, CDCl₃) δ 7.23 (d, *J* = 0.9 Hz, 1H), 6.95 (dt, *J* = 8.2, 1.0 Hz, 1H), 6.47 (dd, *J* = 8.3, 2.5 Hz, 1H), 6.28 (d, *J* = 2.4 Hz, 1H), 3.77 (d, *J* = 3.1 Hz, 5H), 3.64 (s, 3H), 3.21 (s, 3H), 3.17 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 169.90, 158.96, 142.60, 140.41, 129.78, 115.72, 106.51, 100.47, 99.61, 60.38, 55.43, 38.95, 34.17, 27.13; HRMS (ESI): *m/z* calcd. For C₁₄H₁₉NO₃: 263.1396 [M + H]⁺, found 263.1397. Anal. Calcd. for C₁₄H₁₈N₂O₃: C, 64.10; H, 6.92; N, 10.68. Found: C, 64.19; H, 6.90; N, 10.73.

1-(1-Benzyl-7-methoxy-1,4-dihydroquinolin-3-yl)ethanone (1n)

According to procedure A, from quinolinium salt **2n** (160 mg, 0.43 mmol), BNAH (92 mg, 0.43 mmol), dry dichloromethane (2.0 mL). Compound **1n** was obtained (86 mg, 68%) as an orange solid. m.p. 129–130 °C; ¹H NMR (300 MHz, CDCl₃) δ 7.39–7.25 (m, 6H), 7.01 (dt, *J* = 8.3, 1.1 Hz, 1H), 6.47 (dd, *J* = 8.3, 2.4 Hz, 1H), 6.24 (d, *J* = 2.4 Hz, 1H), 4.80 (s, 2H), 3.75 (s, 2H), 3.63 (s, 3H), 2.23 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 194.75, 158.74, 144.41, 138.41, 136.25, 130.59, 129.11, 127.83, 126.18, 116.02, 110.79, 107.70, 101.31, 55.32, 55.27, 25.00, 24.28; HRMS (ESI): *m/z* calcd. for C₁₉H₂₀NO₂: 294.1494 [M + H]⁺, found 294.1490. Anal. Calcd. for C₁₉H₁₉NO₂: C, 77.79; H, 6.53; N, 4.77. Found: C, 77.86; H, 6.50; N, 4.70.

1-(7-Methoxy-1-phenethyl-1,4-dihydroquinolin-3-yl)ethanone (1o)

According to procedure A, from quinolinium salt **2o** (150 mg, 0.39 mmol), BNAH (83 mg, 0.39 mmol), dry dichloromethane (2.0 mL). Compound **1o** was obtained (90 mg, 75%) as an orange solid. m.p. 92–93 °C; ¹H NMR (300 MHz, CDCl₃) δ 7.29 (dd, *J* = 6.9, 1.3 Hz, 2H), 7.26–7.13 (m, 3H), 7.02 (dt, *J* = 8.3, 1.1 Hz, 1H), 6.72 (s, 1H), 6.53 (dd, *J* = 8.3, 2.4 Hz, 1H), 6.47 (d, *J* = 2.4 Hz, 1H), 3.80 (s, 5H), 3.62 (s, 2H), 2.99 (t, *J* = 6.9 Hz, 2H), 1.99 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 194.63, 158.94, 144.23, 138.13, 137.87, 130.95, 129.05, 128.86, 126.97, 116.40, 109.69, 107.23, 100.53, 55.47, 53.25, 34.24, 24.76, 23.97; HRMS (ESI): *m/z* calcd. for C₂₀H₂₂NO₂: 308.1651 [M + H]⁺, found 308.1647. Anal. Calcd. for C₂₀H₂₁NO₂: C, 78.15; H, 6.89; N, 4.56. Found: C, 78.25; H, 6.91; N, 4.49.

1-(7-Methoxy-1-propyl-1,4-dihydroquinolin-3-yl)ethanone (1p)

According to procedure A, from quinolinium salt **2p** (130 mg, 0.40 mmol), BNAH (86 mg, 0.40 mmol), dry dichloromethane (2.0 mL). Compound **1p** was obtained (60 mg, 61%) as an orange solid. m.p. 98–99 °C; ¹H NMR (300 MHz, CDCl₃) δ 7.15 (d, *J* = 0.8 Hz, 1H), 7.01 (dt, *J* = 8.4, 1.1 Hz, 1H), 6.50 (dd, *J* = 8.3, 2.4 Hz, 1H), 6.35 (d, *J* = 2.4 Hz, 1H), 3.78 (s, 3H), 3.68 (s, 2H), 3.59–3.47 (m, 2H), 2.23 (s, 3H), 1.82–1.69 (m, 2H), 0.99 (t, *J* = 7.4 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 194.59, 158.92, 144.22, 138.25, 130.82, 116.46, 110.00, 107.10, 100.82, 55.53, 53.60, 25.07, 24.29, 21.38, 11.33; HRMS (ESI): *m/z* calcd. for C₁₅H₂₀NO₂: 246.1494 [M + H]⁺, found 246.1507. Anal. Calcd. for C₁₅H₁₉NO₂: C, 73.44; H, 7.81; N, 5.71. Found: C, 73.46; H, 7.80; N, 5.80.

General procedure B for the synthesis of compounds 2a–p

In a glass tube, to a solution of the corresponding quinoline **6a–m** in dry acetonitrile was added a large excess of alkyl halide at 20 °C. The tube was sealed and the resulting mixture was heated at 85 °C until reaction completion (18 h for MeI and up to 4 days for the rest of the alkylating agents). After cooling at room temperature, dichloromethane (5 mL) and diethyl ether (15 mL) were added to the suspension and the mixture was stirred for 10 min. The formed precipitate was filtered, rinsed twice with diethyl ether, and dried under vacuum to afford the corresponding quinolinium salt.

3-Acetyl-1-methylquinolin-1-ium iodide (2a)

According to procedure B, from commercially available 3-acetylquinoline (200 mg, 1.17 mmol), MeI (1.0 mL), dry acetonitrile (2.0 mL). Quinolinium salt **2a** (340 mg, 93%) was obtained as an orange powder. m.p. 235–236 °C; ¹H NMR (300 MHz, DMSO) δ 9.97 (s, 1H), 9.90 (s, 1H), 8.79–8.53 (m, 2H), 8.42 (td, *J* = 7.2, 3.5 Hz, 1H), 8.16 (t, *J* = 7.6 Hz, 1H), 4.73 (s, 3H), 2.84 (s, 3H); ¹³C NMR (75 MHz, DMSO) δ 194.42, 149.89, 146.97, 139.08, 137.56, 132.05, 130.78, 129.54, 128.43, 119.50, 45.64, 27.26; HRMS (ESI): *m/z* calcd. for C₁₂H₁₂NO: 186.0919 [M-I]⁺, found 186.0916.

3-Acetyl-1-methyl-7-(trifluoromethyl)quinolin-1-ium iodide (2b)

According to procedure B, from quinoline **6b** (200 mg, 0.43 mmol), MeI (1.0 mL), dry acetonitrile (4.0 mL). Quinolinium salt **2b** (261 mg, 82%) was obtained as a reddish-orange powder. m.p. 227–228 °C; ¹H NMR (300 MHz, DMSO) δ 10.10 (dd, *J* = 1.9, 0.8 Hz, 1H), 9.99 (s, 1H), 8.93 (s, 1H), 8.86 (d, *J* = 8.6 Hz, 1H), 8.48 (dd, *J* = 8.5, 1.5 Hz, 1H), 4.83 (s, 3H), 2.86 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 196.34, 150.43, 148.74, 136.92, 133.26 (q, *J* = 32.9 Hz), 130.55, 129.01, 128.34, 127.19 (q, *J* = 4.4 Hz), 125.40, 123.20 (q, *J* = 3.1 Hz), 121.78, 26.86; ¹⁹F NMR (282 MHz, CDCl₃) δ −61.35; HRMS (ESI): *m/z* calcd. for C₁₃H₁₁NOF₃: 254.0793 [M-I]⁺, found 254.0798. Anal. Calcd. for C₁₃H₁₁NOF₃I: C, 40.97; H, 2.91; N, 3.68. Found: C, 40.82; H, 2.98; N, 3.75.

3-Acetyl-7-dimethylamino-1-methylquinolin-1-ium iodide (2c)

According to procedure B, from quinoline **6c** (200 mg, 0.93 mmol), MeI (1.0 mL), dry acetonitrile (4.0 mL). Quinolinium salt **2c** (304 mg, 91%) was obtained as a brick orange powder. m.p. 279–280 °C; ¹H NMR (300 MHz, DMSO) δ 9.48 (d, *J* = 1.9 Hz, 1H), 9.23 (d, *J* = 1.5 Hz, 1H), 8.26 (d, *J* = 9.5 Hz, 1H), 7.66 (dd, *J* = 9.4, 2.3 Hz, 1H), 6.93–6.78 (m, 1H), 4.38 (s, 3H), 3.33 (s, 6H), 2.69 (s, 3H); ¹³C NMR (75 MHz, DMSO) δ 193.93, 155.70, 148.17, 142.46, 142.04, 133.36, 123.36, 121.26, 119.32, 94.15, 44.21, 40.53, 26.77; HRMS (ESI): *m/z*

calcd. for $C_{14}H_{17}N_2O$: 229.1341 $[M-I]^+$, found 229.1337. Anal. Calcd. for $C_{14}H_{17}N_2OI$: C, 47.21; H, 4.81; N, 7.86. Found: C, 47.11; H, 4.78; N, 7.77.

3-Acetyl-7-bromo-1-methylquinolin-1-ium iodide (2d)

According to procedure B, from quinoline **6d** (170 mg, 0.680 mmol), methyl iodide (1.0 mL), dry acetonitrile (2.0 mL). Quinolinium salt **2d** (240 mg, 90%) was obtained as a deep yellow powder. m.p. 248–249 °C; 1H NMR (300 MHz, DMSO) δ 9.97 (dd, $J = 1.9$, 0.8 Hz, 1H), 9.87 (d, $J = 1.8$ Hz, 1H), 8.89 (t, $J = 1.2$ Hz, 1H), 8.56 (d, $J = 8.7$ Hz, 1H), 8.35 (dd, $J = 8.7$, 1.7 Hz, 1H), 4.70 (s, 3H), 2.82 (s, 3H); ^{13}C NMR (75 MHz, DMSO) δ 194.19, 150.65, 146.82, 139.56, 134.20, 133.38, 132.10, 129.76, 127.40, 122.40, 45.77, 27.18; HRMS (ESI): m/z calcd. for $C_{12}H_{11}NO^{79}Br$: 264.0024 $[M-I]^+$, found 264.0023. Anal. Calcd. for $C_{12}H_{11}NOBrI$: C, 36.76; H, 2.83; N, 3.57. Found: C, 36.70; H, 2.78; N, 3.49.

3-Acetyl-6-chloro-1-methylquinolin-1-ium iodide (2e)

According to procedure B, from quinoline **6e** (200 mg, 0.973 mmol), methyl iodide (1.0 mL), dry acetonitrile (2.0 mL). Quinolinium salt **2e** (321 mg, 95%) was obtained as a bright orange powder. m.p. 259–260 °C; 1H NMR (300 MHz, DMSO) δ 10.00 (dd, $J = 1.9$, 0.8 Hz, 1H), 9.84–9.77 (m, 1H), 8.79 (d, $J = 2.4$ Hz, 1H), 8.62 (d, $J = 9.3$ Hz, 1H), 8.45 (dd, $J = 9.4$, 2.4 Hz, 1H), 4.73 (s, 3H); ^{13}C NMR (75 MHz, DMSO) δ 194.05, 150.34, 145.92, 137.88, 137.22, 135.21, 130.53, 130.24, 129.41, 121.89, 45.85, 27.17; HRMS (ESI): m/z calcd. for $C_{12}H_{11}NOCl$: 220.0529 $[M-I]^+$, found 220.0536. Anal. Calcd. for $C_{12}H_{11}NOClI$: C, 41.47; H, 3.19; N, 4.03. Found: C, 41.50; H, 3.28; N, 3.97.

3-Acetyl-6,7-dimethoxy-1-methylquinolin-1-ium iodide (2f)

According to procedure B, from quinoline **6f** (200 mg, 0.87 mmol), MeI (1.0 mL), dry acetonitrile (4.0 mL). Quinolinium salt **2f** (290 mg, 90%) was obtained as a yellow powder. m.p. 235–236 °C; 1H NMR (300 MHz, DMSO) δ 9.71–9.64 (m, 1H), 9.53 (d, $J = 1.8$ Hz, 1H), 8.04 (s, 1H), 7.71 (s, 1H), 4.66 (s, 3H), 4.20 (s, 3H), 4.03 (s, 3H), 2.79 (s, 3H); ^{13}C NMR (75 MHz, DMSO) δ 194.21, 158.23, 151.48, 145.88, 142.81, 137.42, 127.55, 125.03, 108.95, 99.19, 57.66, 56.64, 45.56, 27.08; HRMS (ESI): m/z calcd. for $C_{14}H_{16}NO_3$: 246.1130 $[M-I]^+$, found 246.1138. Anal. Calcd. for $C_{14}H_{16}NO_3I$: C, 45.06; H, 4.32; N, 3.75. Found: C, 45.11; H, 4.46; N, 3.78.

7-Acetyl-5-methyl-[1,3]dioxolo[4,5-g]quinolin-5-ium iodide (2g)

According to procedure B, from quinoline **6g** (150 mg, 0.745 mmol), methyl iodide (1.0 mL), dry acetonitrile (4.0 mL). Quinolinium salt **2g** (222 mg, 89%) was obtained as a beige powder. m.p. 235–236 °C; 1H NMR (300 MHz, DMSO) δ 9.70–9.63 (m, 1H), 9.47 (d, $J = 1.8$ Hz, 1H), 8.06 (d, $J = 0.8$ Hz, 1H), 7.94 (s, 1H), 6.54 (s, 2H), 4.56 (s, 3H), 2.77 (s, 3H); ^{13}C NMR (75 MHz, DMSO) δ 194.23, 157.51, 150.50, 146.24, 143.30, 139.54, 127.89, 126.93, 105.65, 105.15, 97.21, 45.98, 27.11; HRMS (ESI): m/z calcd. for $C_{13}H_{12}NO_3$: 230.0817 $[M-I]^+$, found 230.0823. Anal. Calcd. for $C_{13}H_{12}NO_3I$: C, 43.72; H, 3.39; N, 3.92. Found: C, 43.77; H, 3.29; N, 3.93.

3-Acetyl-7-methoxy-1-methylquinolin-1-ium iodide (2h)

According to procedure B, from quinoline **6h** (58 mg, 0.29 mmol), MeI (0.5 mL), dry acetonitrile (1.0 mL). Quinolinium salt **2h** (70 mg, 70%) was obtained as an orange powder. m.p. 223–224 °C; 1H NMR (300 MHz, DMSO) δ 9.83 (d, $J = 1.8$ Hz, 1H), 9.70 (d, $J = 1.8$ Hz, 1H), 8.55 (d, $J = 9.1$ Hz, 1H), 7.84–7.71 (m, 2H), 4.64 (s, 3H), 4.17 (s, 3H), 2.79 (s, 3H); ^{13}C NMR (75 MHz, DMSO) δ 194.19, 166.59, 149.27, 145.50, 141.93, 133.88, 127.15, 123.90, 122.76, 99.62, 57.32, 45.37, 27.05; HRMS (ESI): m/z calcd. for $C_{13}H_{14}NO_2$: 216.1025 $[M-I]^+$, found 216.1015. Anal. Calcd. for $C_{13}H_{14}NO_2I$: C, 45.50; H, 4.11; N, 4.08. Found: C, 45.50; H, 4.17; N, 4.13.

3-Cyano-7-methoxy-1-methylquinolin-1-ium (2i)

According to procedure B, from quinoline **6i** (100 mg, 0.54 mmol), MeI (0.5 mL), dry acetonitrile (2.0 mL). Quinolinium salt **2i** (133 mg, 75%) was obtained as an orange powder. m.p. 223–224 °C; 1H NMR (300 MHz, DMSO) δ 9.95 (s, 1H), 9.68 (s, 1H), 8.42 (d, $J = 9.2$ Hz, 1H), 7.91–7.65 (m, 2H), 4.55 (s, 3H), 4.18 (s, 3H); ^{13}C NMR (75 MHz, DMSO) δ 167.38, 151.67, 149.64, 141.92, 133.29, 123.83, 123.48, 114.89, 102.97, 99.79, 57.62, 45.74; HRMS (ESI): m/z calcd. for $C_{12}H_{11}N_2O$: 199.0875 $[M-I]^+$, found 199.0871.

7-Methoxy-3-(methoxycarbonyl)-1-methylquinolin-1-ium (2j)

According to procedure B, from quinoline **6j** (100 mg, 0.46 mmol), MeI (0.5 mL), dry acetonitrile (2.0 mL). Quinolinium salt **2j** (141 mg, 85%) was obtained as a deep yellow powder. m.p. 240–241 °C; ¹H NMR (300 MHz, DMSO) δ 9.85 (d, *J* = 1.8 Hz, 1H), 9.67 (d, *J* = 1.9 Hz, 1H), 8.59 (d, *J* = 9.1 Hz, 1H), 7.90–7.64 (m, 2H), 4.63 (s, 3H), 4.16 (s, 3H), 4.02 (s, 3H); ¹³C NMR (75 MHz, DMSO) δ 166.79, 162.88, 149.66, 146.27, 142.35, 133.81, 124.06, 122.89, 120.77, 99.55, 57.40, 53.31, 45.36; HRMS (ESI): *m/z* calcd. for C₁₃H₁₄NO₃: 232.0974 [M-I]⁺, found 232.0979. Anal. Calcd. for C₁₃H₁₄NO₃I: C, 43.47; H, 3.93; N, 3.90. Found: C, 43.60; H, 3.90; N, 3.90.

3-(Ethoxycarbonyl)-7-methoxy-1-methylquinolin-1-ium (2k)

According to procedure B, from quinoline **6k** (100 mg, 0.43 mmol), MeI (0.5 mL), dry acetonitrile (2.0 mL). Quinolinium salt **2k** (161 mg, 84%) was obtained as a deep yellow powder. m.p. 218–219 °C; ¹H NMR (300 MHz, DMSO) δ 9.83 (d, *J* = 1.9 Hz, 1H), 9.66 (d, *J* = 2.2 Hz, 1H), 8.59 (d, *J* = 9.1 Hz, 1H), 7.79 (dd, *J* = 9.0, 2.2 Hz, 1H), 7.74 (d, *J* = 2.3 Hz, 1H), 4.63 (s, 3H), 4.49 (q, *J* = 7.1 Hz, 2H), 4.16 (s, 3H), 1.41 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (75 MHz, DMSO) δ 166.76, 162.38, 149.65, 146.20, 142.35, 133.81, 124.07, 122.87, 120.99, 99.54, 62.34, 57.38, 45.38, 14.21; HRMS (ESI): *m/z* calcd. for C₁₄H₁₆NO₃: 246.1130 [M-I]⁺, found 246.1235. Anal. Calcd. For C₁₄H₁₆NO₃I: C, 45.06; H, 4.32; N, 3.75. Found: C, 45.11; H, 4.46; N, 3.78.

3-(Dimethylcarbamoyl)-7-methoxy-1-methylquinolin-1-ium iodide (2l)

According to procedure B, from quinoline **6l** (200 mg, 0.87 mmol), MeI (1.0 mL), dry acetonitrile (4.0 mL). Quinolinium salt **2l** (278 mg, 91%) was obtained as a khaki powder. M.p. 219–220 °C; ¹H NMR (300 MHz, DMSO) δ 9.56 (d, *J* = 1.8 Hz, 1H), 9.28 (d, *J* = 1.8 Hz, 1H), 8.42 (d, *J* = 9.0 Hz, 1H), 7.81–7.65 (m, 2H), 4.59 (s, 3H), 4.15 (s, 3H), 3.10 (s, 6H). ¹³C NMR (75 MHz, DMSO) δ 165.48, 164.57, 148.25, 143.75, 140.93, 132.60, 126.91, 124.00, 122.64, 98.98, 57.23, 45.38, 35.34; HRMS (ESI): *m/z* calcd. For C₁₄H₁₇N₂O₂: 245.1290 [M-I]⁺, found 245.1282. Anal. Calcd. for C₁₄H₁₇N₂O₂I: C, 45.18; H, 4.60; N, 7.53. Found: C, 45.03; H, 4.66; N, 7.48.

7-Methoxy-3-(methoxy(methyl)carbamoyl)-1-methylquinolin-1-ium iodide (2m)

According to procedure B, from quinoline **6m** (350 mg, 0.745 mmol), MeI (3.0 mL), no solvent, 24 h. Quinolinium salt **2m** (471 mg, 85%) was obtained as a khaki powder. m.p. 206–207 °C; ¹H NMR (300 MHz, DMSO) δ 9.63 (d, *J* = 1.8 Hz, 1H), 9.43 (d, *J* = 1.8 Hz, 1H), 8.51 (d, *J* = 9.1 Hz, 1H), 7.84–7.65 (m, 2H), 4.61 (s, 3H), 4.15 (s, 3H), 3.65 (s, 3H), 3.41 (s, 3H), 3.34 (s, 3H); ¹³C NMR (75 MHz, DMSO) δ 166.00, 162.95, 149.04, 145.11, 141.35, 133.22, 124.38, 123.83, 122.69, 99.21, 61.59, 57.28, 45.50; HRMS (ESI): *m/z* calcd. for C₁₄H₁₇N₂O₃: 261.1239 [M-I]⁺, found 261.1243. Anal. Calcd. for C₁₄H₁₇N₂O₃I: C, 43.32; H, 4.41; N, 7.22. Found: C, 43.47; H, 4.46; N, 7.17.

3-Acetyl-1-benzyl-7-methoxyquinolin-1-ium bromide (2n)

According to procedure B, from quinoline **6h** (150 mg, 0.745 mmol), Benzyl bromide (1.0 mL), dry acetonitrile (4.0 mL), 3 days. Quinolinium salt **2n** (252 mg, 91%) was obtained as a beige powder. m.p. 218–219 °C; ¹H NMR (300 MHz, DMSO) δ 10.10 (d, *J* = 1.9 Hz, 1H), 9.79 (d, *J* = 1.8 Hz, 1H), 8.57 (d, *J* = 8.9 Hz, 1H), 7.80–7.65 (m, 2H), 7.54–7.29 (m, 5H), 6.44 (s, 2H), 4.00 (s, 3H), 2.84 (s, 3H); ¹³C NMR (75 MHz, DMSO) δ 194.25, 166.49, 149.56, 146.28, 140.94, 134.41, 133.63, 129.10, 128.86, 127.76, 127.65, 124.68, 122.56, 100.21, 59.97, 57.19, 27.16; HRMS (ESI): *m/z* calcd. for C₁₉H₁₈NO₂: 292.1338 [M-Br]⁺, found 292.1336. Anal. Calcd. for C₁₉H₁₈NO₂Br: C, 61.30; H, 4.87; N, 3.76. Found: C, 61.41; H, 4.95; N, 3.79.

3-Acetyl-7-methoxy-1-phenethylquinolin-1-ium bromide (2o)

According to procedure B, from quinoline **6h** (150 mg, 0.745 mmol), phenethyl bromide (1.0 mL), dry acetonitrile (4.0 mL), 4 days. Quinolinium salt **2o** (230 mg, 80%) was obtained as a greenish-brown powder. m.p. 183–184 °C; ¹H NMR (300 MHz, DMSO) δ 9.68 (d, *J* = 1.8 Hz, 1H), 9.60 (d, *J* = 1.9 Hz, 1H), 8.54 (d, *J* = 9.8 Hz, 1H), 7.76 (d, *J* = 7.9 Hz, 2H), 7.31–7.16 (m, 5H), 5.41 (t, *J* = 7.4 Hz, 2H), 4.17 (s, 3H), 3.33 (t, *J* = 7.3 Hz, 2H), 2.71 (s, 3H); ¹³C NMR (75 MHz, DMSO) δ 193.96, 166.85, 148.67, 145.78, 141.08, 136.49, 134.18, 129.16, 128.57, 127.10, 127.01, 124.40, 122.96, 99.38, 57.29, 34.71, 26.99; HRMS (ESI): *m/z* calcd. for

$C_{20}H_{20}NO_2$: 306.1494 [M-Br]⁺, found 306.1489. Anal. Calcd. for $C_{20}H_{20}NO_2Br$: C, 62.19; H, 5.22; N, 3.63. Found: C, 62.07; H, 5.27; N, 3.59.

3-Acetyl-7-methoxy-1-propylquinolin-1-ium bromide (2p)

According to procedure B, from quinoline **6h** (150 mg, 0.745 mmol), propyl bromide (1.0 mL), dry acetonitrile (4.0 mL), 2 days. Quinolinium salt **2p** (170 mg, 70%) was obtained as a beige powder. m.p. 183–184 °C; ¹H NMR (300 MHz, DMSO) δ 9.84 (d, *J* = 1.9 Hz, 1H), 9.72 (d, *J* = 1.8 Hz, 1H), 8.57 (d, *J* = 9.7 Hz, 1H), 7.79 (d, *J* = 7.8 Hz, 2H), 5.10 (t, *J* = 7.5 Hz, 2H), 4.17 (s, 3H), 2.80 (s, 3H), 2.07–1.94 (m, 2H), 0.99 (t, *J* = 7.3 Hz, 3H); ¹³C NMR (75 MHz, DMSO) δ 194.26, 166.83, 148.75, 145.74, 141.03, 134.29, 127.40, 124.51, 122.69, 99.49, 58.44, 57.40, 27.11, 22.29, 10.57; HRMS (ESI): *m/z* calcd. for $C_{15}H_{18}NO_2$: 244.1338 [M-Br]⁺, found 244.1333. Anal. Calcd. for $C_{15}H_{18}NO_2Br$: C, 55.57; H, 5.60; N, 4.32. Found: C, 55.67; H, 5.47; N, 4.25.

General procedure C for the synthesis of compounds 6b–h

Tin(II) chloride dihydrate was added to a solution of the corresponding 2-nitrobenzaldehyde derivative **3b–h** in EtOH. Thereafter, 4,4-dimethoxybutan-2-one **4** was introduced. The reaction mixture was heated to reflux for 4 h. After cooling to room temperature, the reaction mixture was concentrated and the residue was dissolved in EtOAc and hydrolyzed with saturated aqueous potassium sodium tartrate. The resulting emulsion was stirred overnight and the liquid was decanted. The organic phase was separated and the remaining aqueous layer was extracted with EtOAc. The combined organic layers were washed with brine, dried on MgSO₄, and evaporated. The residue was purified by flash chromatography on silica gel using a mixture of petroleum ether/Et₂O/EtOAc (ratio 5:3:2 to 4:3:3).

3-Acetyl-7-trifluoromethylquinoline (6b)

According to procedure C, 4-trifluoromethyl-2-nitrobenzaldehyde **3b** (1.0 g, 4.6 mmol), 4,4-dimethoxybutan-2-one **4** (1.51 g, 11.4 mmol), SnCl₂·2H₂O (4.12 g, 18.25 mmol) in ethanol (30 mL). Quinoline **6b** (0.425 g, 39%) was obtained as a beige powder. m.p. 102–103 °C; ¹H NMR (300 MHz, CDCl₃) δ 9.53 (d, *J* = 2.2 Hz, 1H), 8.77 (dd, *J* = 2.2, 0.8 Hz, 1H), 8.48 (dd, *J* = 1.8, 0.9 Hz, 1H), 8.10 (d, *J* = 8.6 Hz, 1H), 7.82 (dd, *J* = 8.6, 1.8 Hz, 1H), 2.79 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 196.34, 150.43, 148.74, 136.92, 133.26 (q, *J* = 32.9 Hz), 130.55, 129.01, 128.34, 127.19 (q, *J* = 4.4 Hz), 125.40, 123.20 (q, *J* = 3.1 Hz), 26.86; ¹⁹F NMR (282 MHz, CDCl₃) δ –62.94; HRMS (ESI): *m/z* calcd. for $C_{12}H_9NOF_3$: 240.0636 [M + H]⁺, found 240.0634. Anal. Calcd. for $C_{12}H_8NOF_3$: C, 60.26; H, 3.37; N, 5.86. Found: C, 60.16; H, 3.47; N, 5.77.

3-Acetyl-7-dimethylaminoquinoline (6c)

According to procedure C, 4-dimethylamino-2-nitrobenzaldehyde **3c** (1.0 g, 5.15 mmol), 4,4-dimethoxybutan-2-one **4** (1.70 g, 12.9 mmol), SnCl₂·2H₂O (4.65 g, 20.6 mmol) in ethanol (30 mL). Quinoline **6c** (0.480 g, 44%) was obtained as a beige powder. m.p. 150–151 °C; ¹H NMR (300 MHz, CDCl₃) δ 9.24 (d, *J* = 2.3 Hz, 1H), 8.48 (dd, *J* = 2.3, 0.8 Hz, 1H), 7.71 (d, *J* = 9.0 Hz, 1H), 7.22–7.07 (m, 2H), 3.14 (s, 6H), 2.65 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 196.63, 152.94, 151.92, 150.27, 136.92, 130.48, 125.77, 118.97, 116.63, 106.22, 40.38, 26.62; HRMS (ESI): *m/z* calcd. for $C_{13}H_{15}N_2O$: 215.1184 [M + H]⁺, found 215.1183. Anal. Calcd. for $C_{13}H_{14}N_2O$: C, 72.87; H, 6.59; N, 13.07. Found: C, 72.99; H, 6.60; N, 13.23.

3-Acetyl-7-bromoquinoline (6d)

According to procedure C, 4-bromo-2-nitrobenzaldehyde **3d** (1.0 g, 4.35 mmol), 4,4-dimethoxybutan-2-one **4** (1.44 g, 10.9 mmol), SnCl₂·2H₂O (3.92 g, 17.4 mmol) in ethanol (30 mL). Quinoline **6d** (0.780 g, 72%) was obtained as a beige powder. m.p. 126–127 °C; ¹H NMR (300 MHz, CDCl₃) δ 9.43 (d, *J* = 2.2 Hz, 1H), 8.69 (dd, *J* = 2.3, 0.9 Hz, 1H), 8.36 (dd, *J* = 1.8, 0.9 Hz, 1H), 7.83 (dt, *J* = 8.7, 0.5 Hz, 1H), 7.73 (dd, *J* = 8.7, 1.9 Hz, 1H), 2.75 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 196.44, 150.28, 150.24, 137.23, 132.01, 131.38, 130.54, 129.52, 126.69, 125.56, 26.95; HRMS (ESI): *m/z* calcd. for $C_{11}H_9NO^{79}Br$: 249.9868 [M + H]⁺, found 249.9873. Anal. Calcd. For $C_{11}H_8NOBr$: C, 52.83; H, 3.22; N, 5.60. Found: C, 52.86; H, 3.32; N, 5.75.

3-Acetyl-6-chloroquinoline (6e)

According to procedure C, 5-chloro-2-nitrobenzaldehyde **3e** (3.0 g, 16.2 mmol), 4,4-dimethoxybutan-2-one **4** (5.34 g, 40.4 mmol), SnCl₂·2H₂O (14.59 g, 64.7 mmol) in ethanol

(90 mL). Quinoline **6e** (2 g, 60%) was obtained as a beige powder. M.p. 146–147 °C; ^1H NMR (300 MHz, CDCl_3) δ 9.40 (d, $J = 2.2$ Hz, 1H), 8.61 (dd, $J = 2.2, 0.8$ Hz, 1H), 8.09 (dt, $J = 9.0, 0.7$ Hz, 1H), 7.92 (d, $J = 2.3$ Hz, 1H), 7.76 (dd, $J = 9.0, 2.3$ Hz, 1H), 2.74 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 196.56, 149.52, 148.27, 136.42, 133.57, 133.00, 131.19, 129.98, 127.92, 127.65, 27.04; HRMS (ESI): m/z calcd. For $\text{C}_{11}\text{H}_9\text{NO}^{35}\text{Cl}$: 206.0373 $[\text{M} + \text{H}]^+$, found 206.0368. Anal. Calcd. for $\text{C}_{11}\text{H}_8\text{NOCl}$: C, 64.25; H, 3.92; N, 6.81. Found: C, 64.55; H, 3.82; N, 6.90.

3-Acetyl-6,7-dimethoxyquinoline (**6f**)

According to procedure C, 6-nitroveratraldehyde **3f** (2.0 g, 9.5 mmol), 4,4-dimethoxybutan-2-one **4** (3.13 g, 23.7 mmol), $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$ (8.55 g, 37.9 mmol) in ethanol (60 mL). Quinoline **6f** (2.1 g, 96%) was obtained as a yellow powder. m.p. 218–219 °C; ^1H NMR (300 MHz, CDCl_3) δ 9.23 (d, $J = 2.2$ Hz, 1H), 8.56 (d, $J = 2.2$ Hz, 1H), 7.46 (s, 1H), 7.14 (s, 1H), 4.06 (s, 3H), 4.03 (s, 3H), 2.71 (s, 3H). ^{13}C NMR (75 MHz, CDCl_3) δ 196.90, 154.73, 150.67, 147.62, 147.52, 135.27, 128.20, 122.70, 108.05, 106.31, 56.48, 56.31, 26.90. HRMS (ESI): m/z calcd. for $\text{C}_{13}\text{H}_{14}\text{NO}_3$: 232.0970 $[\text{M} + \text{H}]^+$, found 232.0974. Anal. Calcd. for $\text{C}_{13}\text{H}_{13}\text{NO}_3$: C, 67.52; H, 5.67; N, 6.06. Found: C, 67.56; H, 5.52; N, 6.00.

7-Acetyl-[1,3]dioxolo[4,5-g]quinoline (**6g**)

According to procedure C, 6-nitropiperonal **3g** (1.0 g, 5.1 mmol), 4,4-dimethoxybutan-2-one **4** (1.69 g, 12.8 mmol), $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$ (4.63 g, 20.5 mmol) in ethanol (30 mL). Quinoline **6g** (0.178 g, 16%) was obtained as a beige powder. m.p. 165–166 °C; ^1H NMR (300 MHz, CDCl_3) δ 9.22 (d, $J = 2.2$ Hz, 1H), 8.52 (dt, $J = 2.2, 0.6$ Hz, 1H), 7.43 (d, $J = 0.6$ Hz, 1H), 7.16 (s, 1H), 6.17 (s, 2H), 2.71 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 196.82, 152.97, 148.89, 148.75, 147.47, 135.68, 128.12, 124.16, 105.94, 103.91, 102.38, 26.89; HRMS (ESI): m/z calcd. for $\text{C}_{12}\text{H}_{10}\text{NO}_3$: 216.0661 $[\text{M} + \text{H}]^+$, found 216.0653. Anal. Calcd. for $\text{C}_{12}\text{H}_9\text{NO}_3$: C, 66.97; H, 4.22; N, 6.51. Found: C, 67.13; H, 4.42; N, 6.40.

3-Acetyl-7-methoxyquinoline (**6h**)

According to procedure C, 4-methoxy-2-nitrobenzaldehyde **3h** (1.0 g, 5.5 mmol), 4,4-dimethoxybutan-2-one **4** (1.82 g, 13.8 mmol), $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$ (4.98 g, 22.1 mmol) in ethanol (30 mL). Quinoline **6h** (0.71 g, 64%) was obtained as a beige powder. m.p. 129–130 °C; ^1H NMR (300 MHz, CDCl_3) δ 9.32 (d, $J = 2.2$ Hz, 1H), 8.58 (dd, $J = 2.2, 0.8$ Hz, 1H), 7.77 (d, $J = 9.0$ Hz, 1H), 7.41 (d, $J = 2.6$ Hz, 1H), 7.22 (dd, $J = 9.0, 2.5$ Hz, 1H), 3.95 (s, 3H), 2.68 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 196.69, 162.91, 151.97, 149.80, 136.93, 130.51, 127.64, 122.00, 121.02, 107.48, 55.80, 26.79; HRMS (ESI): m/z calcd. for $\text{C}_{12}\text{H}_{12}\text{NO}_2$: 202.0868 $[\text{M} + \text{H}]^+$, found 202.0863. Anal. Calcd. for $\text{C}_{12}\text{H}_{11}\text{NO}_2$: C, 71.63; H, 5.51; N, 6.96. Found: C, 71.76; H, 5.63; N, 7.07.

Methyl 7-methoxyquinoline-3-carboxylate (**6j**)

Methanol (0.9 mL, 22.26 mmol), TMSCl (1.18 g, 10.86 mmol), and quinoline **6i** (1.0 g, 5.43 mmol) were sequentially added to a dry flask under inert atmosphere at rt. The reaction mixture was heated at 50 °C for 4 h. After being cooled to rt, water (0.2 mL) was added to the mixture and followed by the addition of Na_2CO_3 (0.58 g) and CH_2Cl_2 (30 mL). The organic layer was dried on MgSO_4 and concentrated under vacuum to afford 770 mg of ester **6j** (65%). ^1H NMR (300 MHz, CDCl_3) δ 8.94 (d, $J = 2.1$ Hz, 1H), 8.40 (dd, $J = 2.1, 0.8$ Hz, 1H), 7.75 (d, $J = 9.0$ Hz, 1H), 7.44 (d, $J = 2.5$ Hz, 1H), 7.30 (dd, $J = 9.0, 2.5$ Hz, 1H), 3.98 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 163.41, 151.11, 150.51, 140.70, 129.44, 122.06, 121.67, 117.63, 107.80, 104.14, 55.97. Anal. Calcd. for $\text{C}_{12}\text{H}_{11}\text{NO}_3$: C, 66.35; H, 5.10; N, 6.45. Found: C, 66.37; H, 5.05; N, 6.51.

Ethyl 7-methoxyquinoline-3-carboxylate (**6k**)

To a suspension of **5** (1.10 g, 5.41 mmol) in ethanol was added, dropwise, SOCl_2 (2.76 mL, 38 mmol). The resulting mixture was stirred under reflux for 18 h. After concentration under reduced pressure, water (50 mL) was added and the crude mixture was neutralized to pH 7 with 20% solution Na_2CO_3 . The aqueous solution was extracted with CH_2Cl_2 (3×50 mL), the combined organic layers were dried on MgSO_4 and concentrated under vacuum to afford 940 mg (75%) of the desired product **6k**. ^1H NMR (300 MHz, CDCl_3) δ 9.32 (d, $J = 2.1$ Hz, 1H), 8.67 (d, $J = 2.1$ Hz, 1H), 7.73 (d, $J = 9.0$ Hz, 1H), 7.40 (d, $J = 2.4$ Hz, 1H), 7.19 (dd, $J = 9.0, 2.5$ Hz, 1H), 4.41 (q, $J = 14.1, 6.9$ Hz, 2H), 3.93 (s, 3H), 1.41 (t, $J = 7.2$ Hz,

3H); ^{13}C NMR (75 MHz, CDCl_3) δ 165.57, 162.58, 151.84, 150.49, 138.03, 130.08, 121.98, 121.23, 120.71, 107.40, 61.25, 55.64, 14.35. Anal. Calcd. for $\text{C}_{13}\text{H}_{13}\text{NO}_3$: C, 67.52; H, 5.67; N, 6.06. Found: C, 67.46; H, 5.72; N, 6.18.

7-Methoxy-*N,N*-dimethylquinoline-3-carboxamide (6l)

A 20 mL glass tube was charged with 7-methoxyquinoline-3-carboxylic acid **5** (0.5 g, 2.46 mmol), DMF (2 mL), T3P[®] in DMF 50% (1.74 g, 2.71 mmol) and $(\text{CH}_3)_2\text{N}\cdot\text{HCl}$ (2 M in Et_2O , 0.62 mL) at 20 °C. The tube was sealed, heated to 130 °C and stirred for 18 h. The solution was carefully hydrolyzed at 10 °C with aqueous saturated Na_2CO_3 (5 mL) and extracted with ethyl acetate (4 × 20 mL). Combined organic phases were dried on MgSO_4 and concentrated under reduced pressure. The crude product (light brown oil) was used without further purification. m.p. 110–111 °C; ^1H NMR (300 MHz, CDCl_3) δ 8.76 (d, $J = 2.2$ Hz, 1H), 8.03 (dd, $J = 2.2, 0.8$ Hz, 1H), 7.56 (d, $J = 9.0$ Hz, 1H), 7.30–7.24 (m, 1H), 7.07 (dd, $J = 8.9, 2.5$ Hz, 1H), 3.79 (s, 3H), 2.99 (s_{br}, 3H), 2.93 (s_{br}, 3H). ^{13}C NMR (75 MHz, CDCl_3) δ 169.10, 161.47, 149.77, 148.59, 134.73, 129.10, 126.70, 121.87, 120.46, 106.92, 55.37, 39.53, 35.37. HRMS (ESI): m/z calcd. for $\text{C}_{13}\text{H}_{15}\text{N}_2\text{O}_2$: 231.1134 [$\text{M} + \text{H}$]⁺, found 231.1132.

N,N-Dimethoxy-*N*-methylquinoline-3-carboxamide (6m)

To a suspension of 7-methoxyquinoline-3-carboxylic acid **5** (635 mg, 3.1 mmol) in dry DMF (4 mL), CDI (597 mg, 3.4 mmol) was added and the resulting mixture was stirred at 20 °C under a stream of argon for 1 h. Thereafter, DMF (2.0 mL), *N,O*-dimethylhydroxylamine hydrochloride (396 mg, 4.1 mmol) and triethylamine (0.44 mL, 3.1 mmol) were successively added and the mixture was stirred for 18 h. The brown suspension was diluted with ethyl acetate (50 mL) and washed with water. The aqueous layer was extracted twice with ethyl acetate and the organic layers were combined. The organic phase obtained was washed with a saturated solution of NaHCO_3 (2 × 50 mL), water (2 × 50 mL), saturated solution of NH_4Cl (2 × 50 mL), brine. The organic layer was dried on MgSO_4 and concentrated under vacuum to afford 594 mg of **6m** as a pale orange oil (76%). ^1H NMR (300 MHz, CDCl_3) δ 9.18 (d, $J = 2.1$ Hz, 1H), 8.55 (d, $J = 2.1$ Hz, 1H), 7.79 (d, $J = 8.9$ Hz, 1H), 7.49 (d, $J = 2.5$ Hz, 1H), 7.26 (dd, $J = 9.0, 2.5$ Hz, 1H), 3.99 (s, 3H), 3.58 (s, 3H), 3.44 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 167.63, 162.14, 150.63, 149.88, 136.94, 129.86, 124.73, 122.12, 120.62, 107.24, 61.32, 55.71, 33.39; HRMS (ESI): m/z calcd. for $\text{C}_{13}\text{H}_{15}\text{N}_2\text{O}_3$: 247.1083 [$\text{M} + \text{H}$]⁺, found 247.1082. Anal. Calcd. for $\text{C}_{13}\text{H}_{14}\text{N}_2\text{O}_3$: C, 63.40; H, 5.73; N, 11.38. Found: C, 63.61; H, 5.84; N, 11.48.

4. Conclusions

The search of new and readily accessible dual inhibitors of DYRK1A and CLK1, two kinases involved at different levels in the formation of amyloid plaques and neurofibrillary tangles in AD patients, remains a challenge in the development of new drug candidates in AD treatment. To address this issue, we designed herein a new class of dual inhibitors of DYRK1/CLK1 made up of a simple 1,4-dihydroquinoline structure, straightforwardly accessible in only three steps with good overall yields from commercial compounds. A preliminary SAR investigation highlighted that both an acetyl group at C-3 and a methoxy group at C-7 were required within the 1,4-dihydroquinoline scaffold to display the inhibition of *h*DYRK1A/*h*CLK1 kinases. Gratifyingly, compound **1p** proved to be the most potent, exhibiting three- to two-digit nanomolar IC_{50} values (153 nM and 47 nM toward *h*DYRK1A and *h*CLK1, respectively). Interestingly, dihydroquinoline **1p** exhibited antioxidant and radical scavenging properties (scavenging activity $\text{EC}_{50} = 128 \mu\text{M}$). This is a major asset over most existing inhibitors since oxidative stress is involved in the pathogenesis of AD. The ADME profile obtained for **1p** is highly encouraging (predicting inter alia good BBB permeability). Finally, molecular docking studies showed that *N*-methyl-3-acetyl-7-methoxy 1,4-dihydroquinoline **1h** reproduces the INDY binding mode in both kinases *h*DYRK1A and *h*CLK1. Overall, this work paves the way for further research efforts aiming at developing this novel class of dual-inhibitors of *h*DYRK1A and *h*CLK1 with in vitro antioxidant properties as promising drug candidates to treat AD.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/molecules28010036/s1>, procedures for in vitro studies on *h*DYRK1A and *h*CLK1, PAMPA-BBB test of **1p**, solubility assay with **1p**, stability/oxidation and DPPH radical scavenging assays with **1p**, ¹H NMR oxidation of **1p** to **2p** in the presence of DPPH radical, ADME results for **1p**, copies of ¹H and ¹³C-NMR spectra for all synthesized compounds.

Author Contributions: Conceptualization, V.G., C.P. and V.L.; validation, V.G., C.P. and V.L.; formal analysis, J.S.-d.O.S.; investigation, M.-L.T., L.P., F.A. and J.S.-d.O.S.; writing—original draft preparation, C.P., V.L., T.B. and J.S.-d.O.S.; writing—review and editing, C.P., T.B. and V.L.; supervision, V.G., C.P. and V.L. All authors have read and agreed to the published version of the manuscript.

Funding: This work was partially supported by the University of Rouen Normandy, INSA Rouen Normandy, the Centre National de la Recherche Scientifique (CNRS), European Regional Development Fund (ERDF), Labex SynOrg (ANR-11-LABX-0029), Carnot Institute I2C, the graduate school for research XI-Chem (ANR-18-EURE-0020 XL CHEM), and by Région Normandie.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no competing financial interest.

Sample Availability: Samples of the compounds **1a–p** are available from the authors.

Abbreviations

A β	Amyloid- β
AD	Alzheimer's disease
ADME	Absorption Distribution Metabolism Excretion
APP	Amyloid precursor protein
ATP	Adenosine triphosphate
BBB	Blood-brain barrier
BNAH	<i>N</i> -Benzyl-1,4-dihydronicotinamide
BOILED-egg	Brain or intestinal estimated permeation
CDC2	Cell division control 2 kinase
CDI	1,1'-carbonyldiimidazole
CDK	Cyclin-dependent kinase
ChemPLP	Piecewise linear potential
CLK	CDC-like kinase
CLK1	CDC-like kinase 1
CLK2	CDC-like kinase 2
CLK3	CDC-like kinase 3
CLK4	CDC-like kinase 4
cLogP	Calculated LogP
CMGC	CDK, MAPKK, GSK3, CLK group of kinases
CNS	Central nervous system
DMF	Dimethylformamide
DMSO	Dimethylsulfoxide
DPPH \bullet	2,2-diphenyl-1-picrylhydrazyl
DYRK	Dual-specificity tyrosine phosphorylation kinase
DYRK1A	Dual-specificity tyrosine phosphorylation kinase 1A
EC ₅₀	Half maximal effective concentration
EGCG	Epigallocatechin-3-gallate
ESI	Electrospray ionization
EWG	Electron withdrawing group
Glu	Glutamic acid
GOLD	Genetic optimization for ligand docking
GSK3	Glycogen synthase kinase 3

<i>h</i> CLK1	Human CDC-like kinase 1
<i>h</i> DYRK1A	Human dual-specificity tyrosine phosphorylation kinase 1A
HRMS	High resolution mass spectroscopy
IC ₅₀	Half maximal inhibitory concentration
ID	Identification code
INDY	Inhibitor of DYRK kinases
Leu	Leucine
Lys	Lysine
MAPK	Mitogen-activated protein kinase
NAD ⁺	Nicotinamide adenine dinucleotide
NMR	Nuclear magnetic resonance
PAMPA-BBB	Parallel artificial membrane permeability assay of blood-brain barrier
PBS	Phosphate-buffered saline
PDB	Protein data bank
proINDY	Proinhibitor of DYRK kinases
PyMOL	Python Molecular modelling
rt	Room temperature
SAR	Structure-activity relationship
SR	Serine/Arginine rich proteins
T3P	Propylphosphonic anhydride
Tau	Tubulin-associated unit
Thr	Threonine
TLC	Thin layer chromatography
TMSCI	Chlorotrimethylsilane
TPSA	Topological polar surface area
UV	Ultraviolet
WLOGP	Wildman-Crippen LogP

References

- Alzheimer's association report, 2022 Alzheimer's disease facts and figures. *Alzheimers Dement.* **2022**, *18*, 700–789. [[CrossRef](#)] [[PubMed](#)]
- O'Brien, R.J.; Wong, P.C. Amyloid precursor protein processing and Alzheimer's disease. *Annu. Rev. Neurosci.* **2011**, *34*, 185–204. [[CrossRef](#)] [[PubMed](#)]
- Chen, G.-F.; Xu, T.-H.; Yan, Y.; Zhou, Y.-R.; Jiang, Y.; Melcher, K.; Xu, H.E. Amyloid beta: Structure, biology and structure-based therapeutic development. *Acta Pharm. Sin.* **2017**, *38*, 1205–1235. [[CrossRef](#)] [[PubMed](#)]
- DeTure, M.A.; Dickson, D.W. The neuropathological diagnosis of Alzheimer's disease. *Mol. Neurodegener.* **2019**, *14*, 32. [[CrossRef](#)] [[PubMed](#)]
- Wegiel, J.; Gong, C.-X.; Hwang, Y.-W. The role of DYRK1A in neurodegenerative diseases. *FEBS J.* **2011**, *278*, 236–245. [[CrossRef](#)]
- Becker, W.; Sippl, W. Activation, regulation, and inhibition of DYRK1A. *FEBS J.* **2011**, *278*, 246–256. [[CrossRef](#)]
- Lindberg, M.F.; Meijer, L. Dual-specificity, tyrosine phosphorylation-regulated kinases (DYRKs) and cdc2-like kinases (CLKs) in human disease, an overview. *Int. J. Mol. Sci.* **2021**, *22*, 6047. [[CrossRef](#)]
- Ryoo, S.-R.; Cho, H.-J.; Lee, H.-W.; Jeong, H.K.; Radnaabazar, C.; Kim, Y.-S.; Kim, M.-J.; Son, M.-Y.; Seo, H.; Chung, S.-H.; et al. Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: Evidence for a functional link between Down syndrome and Alzheimer's disease. *J. Neurochem.* **2008**, *104*, 1333–1344. [[CrossRef](#)]
- Ryu, Y.S.; Park, S.Y.; Jung, M.-S.; Yoon, S.-H.; Kwon, M.-Y.; Lee, S.-Y.; Choi, S.-H.; Radnaabazar, C.; Kim, M.-K.; Kim, H.; et al. DYRK1A-mediated phosphorylation of Presenilin 1: A functional link between Down syndrome and Alzheimer's disease. *J. Neurochem.* **2010**, *115*, 574–584. [[CrossRef](#)]
- Lee, M.-S.; Kao, S.-C.; Lemere, C.A.; Xia, W.; Tseng, H.-C.; Zhou, Y.; Neve, R.; Ahljianian, M.K.; Tsai, L.-H. APP processing is regulated by cytoplasmic phosphorylation. *J. Cell Biol.* **2003**, *163*, 83–95. [[CrossRef](#)]
- Vingtdeux, V.; Hamdane, M.; Gompel, M.; Bégard, S.; Drobecq, H.; Ghestem, A.; Grosjean, M.-E.; Kostanjevecki, V.; Grognon, P.; Vanmechelen, E.; et al. Phosphorylation of amyloid precursor carboxy-terminal fragments enhances their processing by a gamma-secretase-dependent mechanism. *Neurobiol. Dis.* **2005**, *20*, 625–637. [[CrossRef](#)] [[PubMed](#)]
- Pei, J.-J.; Gong, C.-X.; Iqbal, K.; Grundke-Iqbal, I.; Wu, Q.L.; Winblad, B.; Cowburn, R.F. Subcellular distribution of protein phosphatases and abnormally phosphorylated τ in the temporal cortex from Alzheimer's disease and control brains. *J. Neural Transm.* **1998**, *105*, 69–83. [[CrossRef](#)]
- Jin, N.; Yin, X.; Yu, D.; Cao, M.; Gong, C.-X.; Iqbal, K.; Ding, F.; Gu, X.; Liu, F. Truncation and activation of GSK-3 β by calpain I: A molecular mechanism links to tau hyperphosphorylation in Alzheimer's disease. *Sci. Rep.* **2015**, *5*, 8187. [[CrossRef](#)] [[PubMed](#)]

14. Ryoo, S.-R.; Jeong, H.K.; Radnaabazar, C.; Yoo, J.-J.; Cho, H.-J.; Lee, H.-W.; Kim, I.-S.; Cheon, Y.-H.; Ahn, Y.S.; Chung, S.-H.; et al. DYRK1A-mediated hyperphosphorylation of Tau. A functional link between Down syndrome and Alzheimer disease. *J. Biol. Chem.* **2007**, *282*, 34850–34857. [[CrossRef](#)] [[PubMed](#)]
15. Azorsa, D.O.; Robeson, R.H.; Frost, D.; Hoovet, B.M.; Brautigam, G.R.; Dickey, C.; Beaudry, C.; Basu, G.D.; Holz, D.R.; Hernandez, J.A.; et al. High-content siRNA screening of the kinome identifies kinases involved in Alzheimer's disease-related tau hyperphosphorylation. *BMC Genomics* **2010**, *11*, 25. [[CrossRef](#)] [[PubMed](#)]
16. Woods, Y.L.; Cohen, P.; Becker, W.; Jakes, R.; Goedert, M.; Wang, X.; Proud, C.G. The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bepsilon at Ser539 and the microtubule-associated protein tau at Thr212: Potential role for DYRK as a glycogen synthase kinase 3-priming kinase. *Biochem. J.* **2001**, *355*, 609–615. [[CrossRef](#)]
17. Ledesma, M.D.; Correas, I.; Avila, J.; Díaz-Nido, J. Implication of brain cdc2 and MAP2 kinases in the phosphorylation of tau protein in Alzheimer's disease. *FEBS Lett.* **1992**, *308*, 218–224. [[CrossRef](#)] [[PubMed](#)]
18. Lee, K.-Y.; Clark, A.W.; Rosales, J.L.; Chapman, K.; Fung, T.; Johnston, R.N. Elevated neuronal Cdc2-like kinase activity in the Alzheimer disease brain. *Neurosci. Res.* **1999**, *34*, 21–29. [[CrossRef](#)]
19. Jain, P.; Karthikeyan, C.; Moorthy, N.S.; Waiker, D.K.; Jain, A.K.; Trivedi, P. Human CDC2-like kinase 1 (CLK1): A novel target for Alzheimer's disease. *Curr. Drug Targets* **2014**, *15*, 539–550. [[CrossRef](#)]
20. Martín Moyano, P.; Némec, V.; Paruch, K. Cdc-like kinases (CLKs): Biology, chemical probes, and therapeutic potential. *Int. J. Mol. Sci.* **2020**, *21*, 7549. [[CrossRef](#)]
21. Bain, J.; McLauchlan, H.; Elliott, M.; Cohen, P. The specificities of protein kinase inhibitors: An update. *Biochem. J.* **2003**, *371*, 199–204. [[CrossRef](#)] [[PubMed](#)]
22. Göckler, N.; Jofre, G.; Papadopoulos, C.; Soppa, U.; Tejedor, F.J.; Becker, W. Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation. *FEBS J.* **2009**, *276*, 6324–6337. [[CrossRef](#)]
23. Tahtouh, T.; Elkins, J.M.; Filippakopoulos, P.; Soundararajan, M.; Burgy, G.; Durieu, E.; Cochet, C.; Schmid, R.S.; Lo, D.C.; Delhommel, F.; et al. Selectivity, cocrystal structures, and neuroprotective properties of Leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid Leucettamine, B. *J. Med. Chem.* **2012**, *55*, 9312–9330. [[CrossRef](#)] [[PubMed](#)]
24. Stotani, S.; Giordanetto, F.; Medda, F. DYRK1A inhibition as potential treatment for Alzheimer's disease. *Future Med. Chem.* **2016**, *8*, 681–696. [[CrossRef](#)] [[PubMed](#)]
25. Nguyen, T.L.; Fruit, C.; Héroult, Y.; Meijer, L.; Besson, T. Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: A survey of recent patent literature. *Expert Opin. Ther. Pat.* **2017**, *27*, 1183–1199. [[CrossRef](#)]
26. Pathak, A.; Rohilla, A.; Gupta, T.; Akhtar, M.J.; Haider, M.R.; Sharma, K.; Haider, K.; Yar, M.S. DYRK1A kinase inhibition with emphasis on neurodegeneration: A comprehensive evolution story-cum-perspective. *Eur. J. Med. Chem.* **2018**, *158*, 559–592. [[CrossRef](#)]
27. Jarhad, D.B.; Mashelkar, K.K.; Kim, H.-R.; Noh, M.; Jeong, L.S. Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors as potential therapeutics. *J. Med. Chem.* **2018**, *61*, 9791–9810. [[CrossRef](#)] [[PubMed](#)]
28. Zhao, L.; Xiong, X.; Liu, L.; Liang, Q.; Tong, R.; Feng, X.; Bai, L.; Shi, J. Recent research and development of DYRK1A inhibitors. *Chin. Chem. Lett.* **2022**, *33*, 1841–1849. [[CrossRef](#)]
29. Zuccotto, F.; Ardini, E.; Casale, E.; Angiolini, M. Through the “gatekeeper door”: Exploiting the active kinase conformation. *J. Med. Chem.* **2010**, *53*, 2681–2694. [[CrossRef](#)]
30. Ogawa, Y.; Nonaka, Y.; Goto, T.; Ohnishi, E.; Hiramatsu, T.; Kii, I.; Yoshida, M.; Ikura, T.; Onogi, H.; Shibuya, H.; et al. Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A. *Nat. Commun.* **2010**, *1*, 86. [[CrossRef](#)]
31. Muraki, M.; Ohkawara, B.; Hosoya, T.; Onogi, H.; Koizumi, J.; Koizumi, T.; Sumi, K.; Yomoda, J.-I.; Murray, M.V.; Kimura, H.; et al. Manipulation of alternative splicing by a newly developed inhibitor of Clks. *J. Biol. Chem.* **2004**, *279*, 24246–24254. [[CrossRef](#)] [[PubMed](#)]
32. Venkatesan, H.; Hocutt, F.M.; Jones, T.K.; Rabinowitz, M.H. A one-step synthesis of 2,4-unsubstituted quinoline-3-carboxylic acid esters from *o*-nitrobenzaldehydes. *J. Org. Chem.* **2010**, *75*, 3488–3491. [[CrossRef](#)] [[PubMed](#)]
33. Charpentier, P.; Lobregat, V.; Levacher, V.; Dupas, G.; Quéguiner, G.; Bourguignon, J. An efficient synthesis of 3-cyanoquinoline derivatives. *Tetrahedron Lett.* **1998**, *39*, 4013–4016. [[CrossRef](#)]
34. Luo, F.-T.; Jeevanandam, A. Simple transformation of nitrile into ester by the use of chlorotrimethylsilane. *Tetrahedron Lett.* **1998**, *39*, 9455–9456. [[CrossRef](#)]
35. Gourand, F.; Patin, D.; Henry, A.; Ibazizène, M.; Dhilly, M.; Fillesoye, F.; Tirel, O.; Tintas, M.-L.; Papamicaël, C.; Levacher, V.; et al. Chemical delivery system of MIBG to the central nervous system: Synthesis, ¹¹C-radiosynthesis, and in vivo evaluation. *ACS Med. Chem. Lett.* **2019**, *10*, 352–357. [[CrossRef](#)] [[PubMed](#)]
36. Gella, A.; Durany, N. Oxidative stress in Alzheimer disease. *Cell Adhes. Migr.* **2009**, *3*, 88–93. [[CrossRef](#)] [[PubMed](#)]
37. Manoharan, S.; Guillemin, G.J.; Abiramasundari, R.S.; Essa, M.M.; Akbar, M.; Akbar, M.D. The role of reactive oxygen species in the pathogenesis of Alzheimer's disease, Parkinson's disease, and Huntington's disease: A mini review. *Oxid. Med. Cell. Longev.* **2016**, *2016*, 8590578. [[CrossRef](#)]
38. Velena, A.; Zarkovic, N.; Troselj, K.G.; Bisenieks, E.; Krauze, A.; Poikans, J.; Duburs, G. 1,4-Dihydropyridine derivatives: Dihydronicotinamide analogues-model compounds targeting oxidative stress. *Oxid. Med. Cell. Longev.* **2016**, *2016*, 1892412. [[CrossRef](#)]

39. Wojsiat, J.; Zoltowska, K.M.; Laskowska-Kaszub, K.; Wojda, U. Oxidant/antioxidant imbalance in Alzheimer's disease: Therapeutic and diagnostic prospects. *Oxid. Med. Cell. Long.* **2018**, *2018*, 6435861. [[CrossRef](#)]
40. Sinyor, B.; Mineo, J.; Ochner, C. Alzheimer's disease, inflammation, and the role of antioxidants. *J. Alzheimers Dis. Rep.* **2020**, *4*, 175–183. [[CrossRef](#)]
41. Gourand, F.; Tîntaş, M.-L.; Henry, A.; Ibazizène, M.; Dhilly, M.; Fillesoye, F.; Papamicaël, C.; Levacher, V.; Barré, L. Delivering FLT to the central nervous system by means of a promising targeting system: Synthesis, [¹¹C]radiosynthesis, and in vivo evaluation. *ACS. Chem. Neurosci.* **2017**, *8*, 2457–2467. [[CrossRef](#)] [[PubMed](#)]
42. Peauger, L.; Azzouz, R.; Gembus, V.; Tîntaş, M.-L.; Sopková-de Oliveira Santos, J.; Bohn, P.; Papamicaël, C.; Levacher, V. Donepezil-based central acetylcholinesterase inhibitors by means of a "bio-oxidizable" prodrug strategy: Design, synthesis, and in vitro biological evaluation. *J. Med. Chem.* **2017**, *60*, 5909–5926. [[CrossRef](#)] [[PubMed](#)]
43. Blois, M.S. Antioxidant determinations by the use of a stable free radical. *Nature* **1958**, *181*, 1199–1200. [[CrossRef](#)]
44. Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Adv. Drug. Deliver. Rev.* **2001**, *46*, 3–26. [[CrossRef](#)] [[PubMed](#)]
45. Pajouhesh, H.; Lenz, G.R. Medicinal chemical properties of successful central nervous system drugs. *Neurotherapeutics* **2005**, *2*, 541–553. [[CrossRef](#)] [[PubMed](#)]
46. Daina, A.; Michielin, O.; Zoete, V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. *Sci. Rep.* **2017**, *7*, 42717. [[CrossRef](#)]
47. Daina, A.; Zoete, V. A BOILED-Egg to predict gastrointestinal absorption and brain penetration of small molecules. *ChemMedChem* **2016**, *11*, 1117–1121. [[CrossRef](#)]
48. Kansy, M.; Senner, F.; Gubernator, K. Physicochemical high throughput screening: Parallel artificial membrane permeation assay in the description of passive absorption processes. *J. Med. Chem.* **1998**, *41*, 1007–1010. [[CrossRef](#)]
49. Schröder, M.; Bullock, A.N.; Fedorov, O.; Bracher, F.; Chaikuad, A.; Knapp, S. DFG-1 Residue controls inhibitor binding mode and affinity, providing a basis for rational design of kinase inhibitor selectivity. *J. Med. Chem.* **2020**, *63*, 10224–10234. [[CrossRef](#)]
50. ChemAxon-Software Solutions and Services for Chemistry & Biology, (n.d.). Available online: <https://chemaxon.com/> (accessed on 6 February 2020).
51. Jones, G.; Willet, P.; Glen, R.C. Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. *J. Mol. Bio.* **1995**, *245*, 43–53. [[CrossRef](#)]
52. Jones, G.; Willet, P.; Glen, R.C.; Leach, A.R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. *J. Mol. Biol.* **1997**, *267*, 727–748. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.